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Abstract 
The skin is the largest organ in the human body and its major function is to protect from 
harmful environmental influences and to prevent dehydration. It forms the first barrier 
against biological, chemical and physical stress. Atopic dermatitis (AD) is a relapsing 
inflammatory skin disease. Hallmarks of AD are pruritic, eczematous erythematous plaques 
resulting in reduced skin barrier function, increasing transepidermal water loss and, affected 
by this, dry skin. AD commonly begins in early childhood and affects 10-20% of children 
and 1-3% of adults in industrialized countries. AD patients show significant higher levels of 
IL-31 in serum and increased IL31 mRNA levels in lesional skin samples. These higher 
levels are correlated with serum IgE, disease severity, and subjective itch intensity. In 
previous work it was observed that IL-31 interferes with keratinocyte differentiation and 
proliferation. The differentiation defect was associated with a profound repression of 
terminal differentiation markers, including filaggrin, an essential factor for skin barrier 
formation, and a reduced lipid envelope. To identify its molecular targets, IL-31-dependent 
gene expression was determined in 3-dimensional organotypic skin models in this work. IL-
31 regulated genes were involved in the formation of an intact physical skin barrier. Many of 
these genes were poorly induced during differentiation as a consequence of IL-31 treatment, 
resulting in increased penetrability to allergens and irritants. Furthermore studies employing 
cell-sorted skin equivalents in SCID / NOD mice demonstrated enhanced transepidermal 
water loss following subcutaneous administration of IL-31. The IL-1 cytokine network was 
identified as a downstream effector of IL-31 signaling. Anakinra, an IL-1 receptor 
antagonist, blocked the IL-31 effects on skin differentiation. In addition to the effects on the 
physical barrier, IL-31 stimulated the expression of antimicrobial peptides. This was evident 
already at low doses of IL-31, which were insufficient to interfere with the physical barrier. 
Moreover IL-31 induced the expression and release of the itch mediator TSLP in human 3-
dimensional organotypic skin models. 
Together these findings demonstrated that IL-31 affects keratinocyte differentiation in 
multiple ways and that the IL-1 cytokine network is a major downstream effector of IL-31 
signaling in deregulating the physical skin barrier. Therefore when targeting IL-31 for 
therapeutic purposes it needs to be considered that low doses of IL-31 promote the 
antimicrobial barrier and thus a complete inhibition of IL-31 signaling may be undesirable.
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Zusammenfassung 
Die Haut ist das größte Organ des menschlichen Körpers und seine Hauptfunktion ist es, vor 
schädlichen Umwelteinflüssen zu schützen und Austrocknung zu verhindern. Die Haut 
bildet die erste Barriere des Körpers gegen biologische, chemische und physikalische 
Belastungen. Atopische Dermatitis (AD) ist eine rezidivierende, entzündliche 
Hauterkrankung. Kennzeichen der AD sind juckende, gerötete Plaques, erhöhter 
transepidermaler Wasserverlust, eine verringerte Hautbarriere und dadurch verursacht, 
trockene Haut. AD beginnt häufig in der frühen Kindheit und betrifft 10-20% der Kinder 
und 1-3% der Erwachsenen in den Industrieländern. AD-Patienten zeigen deutlich erhöhte 
IL-31 Serum Werte und ebenfalls erhöhte IL31-mRNA-Level in Proben lesionaler Haut. 
Diese erhöhten IL-31 Level korrelieren mit dem Serum-IgE, der Schwere der Erkrankung 
und der Intensität des Juckreizes. In früheren Arbeiten wurde beobachtet, dass IL-31 die 
Keratinozyten-Differenzierung und Proliferation stört. Der Defekt in der Differenzierung ist 
mit einer Unterdrückung der terminalen Differenzierungsmarker und einer reduzierten 
Lipidhülle verbunden. Um neue molekulare Ziele zu identifizieren, wurde in dieser Arbeit 
die IL-31-abhängige Genexpression in 3-dimensionalen organotypischen Hautmodellen 
untersucht. IL-31 regulierte Gene, welche an der Bildung einer intakten physikalischen 
Hautbarriere beteiligt sind. Viele dieser Proteine waren als Folge der IL-31-Behandlung 
während der Differenzierung geringer exprimiert als ohne IL-31, was zu einer erhöhten 
Penetrierung von Allergenen und Reizstoffen führte. Darüber hinaus zeigten Experimente 
mit Zellsortierten Hautäquivalenten in SCID / NOD-Mäusen einen erhöhten 
transepidermalen Wasserverlust nach subkutaner Verabreichung von IL-31. Das IL-1-
Zytokin-Netzwerk wurde als ein Downstream-Effektor des IL-31-Signalwegs identifiziert. 
Anakinra, ein IL-1-Rezeptor-Antagonist, blockierte effektiv den oben beschriebenen 
Einfluss von IL-31 auf die Differenzierung. Zusätzlich zu der Wirkung auf die physische 
Barriere stimulierte IL-31 die Expression von antimikrobiellen Peptiden. Dies zeigte sich 
bereits bei niedrigen Dosen von IL-31, welche nicht ausreichten, um die physische Barriere 
zu beeinträchtigen. Außerdem induzierte IL-31 die Expression und die Freisetzung des 
Zytokins TSLP in 3-dimensionale organotypischen Hautmodellen. Dieses Zytokin wurde 
durch andere Arbeitsgruppen als ein Vermittler von Juckreiz identifiziert.  
Zusammengefasst zeigen diese Ergebnisse, dass IL-31 die Differenzierung der 
Keratinozyten in vielfältiger Weise beeinflusst und dass das IL-1-Zytokin-Netzwerk ein 
Downstream-Effektor des IL-31-Signalwegs in der Deregulierung der physikalischen 
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Hautbarriere ist. Bei der Inhibierung von IL-31 als ein neu identifizierter Angriffspunkt 
zur Wirkstoffentwicklung in atopischen Hautkrankheiten wird zu berücksichtigen sein, dass 
niedrige Dosen von IL-31 die antimikrobielle Barriere fördern und deswegen eine 
vollständige Hemmung der IL-31 Signalwegs unerwünscht sein kann. 
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THE HUMAN SKIN 
The skin is the largest organ in the human body and its major function is to protect from 
harmful environmental influences and to prevent dehydration. The skin barrier consists 
mainly of differentiating epidermal keratinocytes. It forms the first barrier against, 
biological, chemical and physical stress. The skin is composed of three different layers, 
epidermis, dermis and hypodermis. 
 
The epidermis is the outermost layer and first defense organ of the human body to the 
environment. To maintain this function keratinocytes undergo different developmental 
stages from cycling keratinocytes in the stratum basale (SB), through differentiating cells 
in the stratum spinosum (SS) and the stratum granulosum (SG) to finally culminate into 
anucleated and flat corneocytes surrounded by cross-linked proteins and extruded lipids in 
the stratum corneum (SC). These are highly differentiated, nucleus-free cells that form an 
insoluble and rigid structure referred to as the cornified envelope (CE). In Figure 1 the 
epidermal barrier and the processes, which are needed to develop an appropriate barrier, 
are summarized. The correct formation and desquamation of the CE is essential for the 
barrier function of the skin (Boniface et al., 2007; Proksch et al., 2008). Thus, all 
components, which are involved, need to be highly regulated in a differentiation-associated 
manner, i.e. their timely and quantitative expression, to ensure the proper development of 
the epidermal barrier. 
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THE CORNIFIED ENVELOPE 
Proteins of the mammalian epidermis consists to 80-90% of keratins and filaggrin (Roop, 
1995; Nemes and Steinert, 1999). The large profilaggrin (>400kDa) is processed to 
monomeric filaggrin that aggregates with keratin filaments into bundles during 
differentiation. Subsequently filaggrin is completely proteolyzed into single amino acids 
by a variety of proteases, including caspase 14 (Denecker et al., 2008). These single amino 
acids are responsible for the hydration of the stratum corneum and thus inhibit 
transepidermal water loss (TEWL). During cornification other proteins including 
involucrin, loricrin, trichohyalin and small proline-rich proteins are crosslinked by either 
disulphide bonds or lysine-isopeptide bonds, which are formed by various 
transglutaminases (Nemes and Steinert, 1999). These cross links provide a rigid structure 
and build an insoluble barrier. Tight junctions (TJ) and corneodesmosomes connect the 
anucleated corneocytes, these side-by-side connections are important for the cohesion of 
the CE. TJ are cell–cell junctions that connect neighboring cells. They control diffusion of 
molecules through the epithelium and thus build a barrier. Furthermore TJ separate the 
apical from the basolateral part of a cell membrane, which prevent diffusion of membrane 
proteins. Due to this TJ allow the specialized functions of each cell surface. In human 
epidermis, various TJ proteins have been identified, including occludin, members of the 
claudin family (1, 4, and 7), JAM-1 (junctional adhesion molecule-1), ZO-1 (zonula 
occludens protein 1) and MUPP-1 (multi-PDZ protein-1) (Pummi et al., 2001; Brandner et 
al., 2002; Langbein et al., 2002; Brandner et al., 2003; Wilke et al., 2006. 2006). 
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Figure 1: Schematic representation of the differentiation process undergoing in keratinocytes. 
Keratinocytes differentiate from a proliferating state in the basal layer (Stratum basale) to dead corneocytes in the outermost 
layer (Stratum corneum). During this differentiation process the lipid envelope, the filaggrin / keratin network, and the 
cornified envelope is formed and desmosomes mature to corneodesmosomes. Together these components form a compact 
barrier against the outside preventing entry of harmful components, for example allergens, pathogens, irradiation and other 
irritants, into the skin and body. Furthermore the barrier inhibits the trans-epidermal water loss (TEWL) and associated loss 
of solutes. 
Within the CE, the strong cohesion of corneocytes is provided by corneodesmosomes. 
These are cellular junctions derived from desmosomes. Desmogleins (DSG) 1-4, 
desmocollins (DSC) 1-3 and corneodesmosin (CDSN) are components of the extracellular 
part of corneodesmosomes in the human epidermis and are responsible for cell-cell 
connection. Intracellular parts of DSC and DSG are connected to a plaque formed by two 
different families of desmosomal proteins, the armadillo repeat protein family, with 
plakoglobin and plakophillin, and the plakin family with desmoplakin, envoplakin, 
periplakin and plectin. These plaques are connected to the intermediate filament 
cytoskeleton of the cell and by these build a rigid structure. During differentiation the 
composition of desmogleins and desmocollins changes within the epidermal layer. From 
DSG 2 and 3 in the stratum basale to DSG 1 and DSG 4 in the upper stratum granulosum. 
Moreover DCS 1 replaces DSC 3 during the differentiation and their number and size rise 
significantly in the spinous layers and decreases in the granular compartment (Niessen, 
2007). 
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The intercellular space between the tightly bound corneocytes is filled with a mixture of 
lipids, which have originated from within the golgi apparatus and are transported by 
lamellar granules. These bodies fuse during the late differentiation process with the plasma 
membrane and subsequently secrete their cargo into the intercellular space. Lipids secreted 
from the lamellar bodies are modified and arranged. The final lipid composition consist of 
a mixture of ceramides, cholesterol and free fatty acids besides several other lipids 
(Madison, 2003). This lipid composition serves as a water barrier and is required for an 
effective skin barrier function. 
 
ATOPIC DERMATITIS 
Atopic dermatitis (AD, ‘‘eczema,’’ ICD-10: L20, OMIM®: 603165) is a relapsing 
inflammatory skin disease. Hallmarks of AD are pruritic, eczematous erythematous 
plaques resulting in reduced skin barrier function, increasing TEWL and, caused by this, 
dry skin (Boniface et al., 2007; Guttman-Yassky et al., 2011; Proksch et al., 2008). AD 
commonly begins in early childhood and affects 10-20% of children and 1-3% of adults in 
industrialized countries (Gazel et al., 2006; Bieber, 2010). 85% of the affected individuals 
develop AD in the first five years of life (Kay et al., 1994) and nearly 80% of children 
suffering from AD develop rhinitis or asthma during lifetime (Eichenfield et al., 2003). 
This aggravation of atopic manifestations is also known as the “atopic / allergic march”. 
This disease development suggest that epicutaneous allergen sensitization may predispose 
people to atopic respiratory diseases (Leung and Bieber, 2003; Palmer et al., 2006; 
Sandilands et al., 2007). Histological analysis of acute and chronic atopic dermatitis skin 
shows decreased cornification and decreased expression of terminal differentiation proteins 
as well as decreased lipids. On a cellular basis AD is also characterized by an increased 
number of eosinophils and mast cells in the dermis and a lack of neutrophils in the 
epidermis (Leung and Bieber, 2003). 
 
INTRODUCTION  13
The reasons for the development of AD are not yet fully understood. AD is a genetically 
complex disease with many chromosomal regions containing pathophysiology relevant 
genes. The gene encoding filaggrin has been identified as a major locus causing skin 
barrier deficiency (Palmer et al., 2006), along with eleven other risk loci in European 
individuals (Ellinghaus et al., 2013). Interestingly not all patients suffering from AD show 
a genetic defect within one of the known risk loci. This led some researchers to the 
conclusion that besides genetic factors AD is triggered by immunological factors. This 
implication can be strengthened by the fact that nearly 40% of children with AD have skin 
rashes after the uptake of food allergens (Sampson, 1999) and furthermore skin lesions can 
develop after challenge with aeroallergens in sensitized patients with AD (Tupker et al., 
1996). 
 
THE HUMAN SKIN MICROBIOME 
The human skin as interface to the environment is permanently in contact with 
microorganisms but usually healthy human skin does not show sign of bacteria infections. 
The human skin houses a plenteous and diverse population of bacteria, fungi, and viruses. 
By 16S RNA gene phylotyping, 19 phyla are known to be part of the bacterial skin 
microbiome. The four phyla, Actinobacteria (51.8%), Firmicutes (24.4%), Proteobacteria 
(16.5%), and Bacteroidetes assigned together 99% of the identified sequences. Moreover 
the majority (62%) of the 205 identified genera were part of the Corynebacterium, 
Propionibacterium and Staphylococcus genera (Grice et al., 2009). The skin flora varies 
between skin sites, which provide many different niches for large populations of microbes. 
These niches differ in humidity, temperature, pH, and the composition of antimicrobial 
peptides and lipids. Furthermore discrete niches are formed by skin structures like hair 
follicles and eccrine glands (Grice et al., 2008). Moreover the skin flora also differs 
between individuals (Schommer and Gallo, 2013), shown by a genomic approach in which 
129 males and 113 females were tested at different body sites. The approach also revealed 
that the diversity within samples from one subject (alpha-diversity) is different from the 
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diversity between samples from the same sample site among other subjects (beta 
diversity) (Human Microbiome Project Consortium, 2012). The composition of resident 
microorganisms varies qualitatively and quantitatively but is stable over time. However, 
the mechanism responsible for this balance remain largely unknown (Costello et al., 2009; 
Human Microbiome Project Consortium, 2012). 
 
The interaction of microbes with a host can be divided into three different categories. The 
interaction can either have a positive, a negative or no effect on involved subjects. A lot of 
environmental factors including community, diet, hygiene products, lifestyle, stress and the 
uptake of drugs influence the composition of the skin microbiome. Besides these, also age 
and genetic predisposition play an important role for the microbiome (Schommer and 
Gallo, 2013). All these factors can influence the host-microbe and also the microbe-
microbe interaction on the skin. A shift of microbial population that alter host–microbiome 
interactions has been associated with disease manifestations, regardless which factor has 
affected the change (Srinivas et al., 2013; Kong et al., 2012; Fry et al., 2013). One step 
further, a potential dysfunction of the capacity to establish the normal microbiome, may 
promote the development to a chronic disease (Schommer and Gallo, 2013). 
 
INTRODUCTION  15
THE SKIN MICROBIOME IN ATOPIC DERMATITIS 
As discussed above the reduced skin barrier in AD patients lead to an effortless penetration 
of bacteria and viruses. Indeed patients suffering from AD have an increased bacterial 
colonization and are particularly prone to infections with Staphylococcus aureus and 
viruses such as herpes and vaccinia (Leung, 2013; Kim et al., 2013). The alteration of the 
skin microbiome may be caused by the dysfunction of the skin barrier. Findings in patients 
with AD demonstrate that a drastic change in the microbiome occurs during AD 
development compared to healthy control patients (Kong et al., 2012; Hata and Gallo, 
2008). Interestingly, AD therapy is associated with changes in bacterial diversity. In 
particular the pathogen S. aureus’ proportion is increased during disease flares compared 
to baseline or post-therapy. Yet another member of the Staphylococcus family, 
S. epidermidis, spreads on the skin during flares. Still increases in Streptococcus, 
Propionibacterium, and Corynebacterium species could also be observed following 
therapy (Kong et al., 2012). 
 
ANTIMICROBIAL PEPTIDES IN HUMAN SKIN 
Antimicrobial peptides (AMPs) are small peptides with a size between 12 and 50 amino 
acids with broad activity against bacteria, viruses and fungi. The group of AMPs is very 
heterogeneous with different modes of action in killing pathogens. The characteristics of 
AMPs mentioned in the following including expression pattern, antimicrobial targets and 
their chemo-attractant properties are summarized in Table 1. The first AMP was isolated 
from the skin of the African claw frog which was called “magainin” in 1987 (Zasloff, 
1987). Keratinocytes of the skin produces a variety of antimicrobial peptides. Structures of 
the groups mentioned in the following are schematically represented in Figure 2, namely 
the S100 family, members of the human beta defensins. Besides their differences in 
structure, the expression patterns of AMPs also vary. Some of the antimicrobial peptides 
are constitutively expressed in the epidermis and not induced in inflammatory conditions; a 
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second group is constitutively expressed in the skin but additionally induced upon 
inflammation. The third group of AMPs is only present in inflammatory skin but not 
present in healthy human skin.  
 
 
Figure 2: Representation of structural elements of human antimicrobial peptides in human skin. 
A. Human defensins are synthesized as pre‐pro peptides that are cleaved to release their antimicrobial peptides (AMPs) 
that interact with negatively charged bacterial surface moieties. Dotted lines indicate disulfide bonds. SP, Signaling peptide; 
B. S100 protein have two helix-loop-helix motifs which are responsible for the binding of Ca2+. S100 proteins can form 
homo- or heterodimers as well as oligomers that change their conformation upon calcium binding. 
HUMAN DEFENSINS 
The family of defensins contains small cationic peptides with six to eight cysteine residues. 
These residues form disulfide bonds, which are responsible for the division into 
subfamilies: α-defensins, β-defensins and θ-defensins. The six members of the α-defensin 
subfamily are primarily expressed in neutrophils, natural killer cells and certain T-cell 
subsets (Zhao and Lu, 2014). β-defensins, a subfamily with 26 members, are expressed and 
secreted by many kinds of epithelial cells as well as by leukocytes (Weinberg et al., 2012). 
The last group is not present in humans, chimpanzees and gorillas but was found to occur 
in old world monkeys such as rhesus macaques (Li et al., 2014). Due to the fact that only 
the human β-defensins are expressed by keratinocytes only these defensins are described in 
the following. 
 
AMP Pro region SP 
N C -helix -helix -helix -helix 
A
B
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Human β-defensin-1 
The human β-defensin 1 (hBD-1), a 36 amino acid basic peptide, was the first discovered 
human β-defensin originally isolated from human blood filtrate in 1995 (Bensch et al., 
1995). The protein is encoded by the DEFB1 gene (Bensch et al., 1995). Later it was found 
in suprabasal keratinocytes, sweat ducts, and sebaceous glands of human skin (Fulton et 
al., 1997; Ali et al., 2001). Either overexpression of DEFB1 lead to increased expression of 
keratinocyte differentiation marker proteins (Frye et al., 2001) or differentiation of 
keratinocytes by Ca2+ lead to upregulation of DEFB1 gene expression (Abiko et al., 2003; 
Frye et al., 2001; Harder et al., 2004). Proinflammatory cytokines such as IL-1α, or 
bacteria e.g. Pseudomonas aeruginosa do not induce hBD-1 expression in keratinocytes 
(Harder et al., 2004). HBD-1 shows activity against E. coli and P. aeruginosa (Singh et al., 
1998). Micromolar concentrations of recombinant hBD-1 are needed to kill various clinical 
strains of E. coli (Singh et al., 1998) and a concentration of 1 μg/ml recombinant hBD-1 is 
required to kill 50% of P. aeruginosa. In comparison native hBD-1 shows only minor 
antimicrobial activity (Zucht et al., 1998). Generally no activity against gram-positive 
bacteria such as the pathogen S. aureus has been reported yet. Besides that, hBD-1 is also 
able to recruit immune cells such as immature DC and memory T-cells to sites of invasion 
via CCR6 receptor signaling and thus modulate the adaptive immune response (Yang et al., 
1999). 
 
Human β-defensin-2 
In 1997, the second member of the human β-defensin family was isolated from lesional 
psoriatic scale extracts using an E. coli affinity column and is encoded by the DEFB4A 
gene (Harder et al., 1997). In contrast to hDB-1 expression, human β-defensin-2 (hBD-2) 
expression is induced in inflamed regions of the skin and is not detected in non-inflamed 
regions. Proinflammatory cytokines such as IL-1α, IL-1β and, TNF-α are effective 
DEFB4A inducers (Huh et al., 2002; Sørensen et al., 2003; Liu et al., 2002; Harder et al., 
1997). Furthermore IL-22 has been detected as a potent stimulus for DEFB4A expression 
(Wolk et al., 2004). In addition, bacteria such as P. aeruginosa or 
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Fusobacterium nucleatum stimulate the expression of hBD-2 (Schroder and Harder, 
1999). In IL-1α stimulated keratinocytes hBD-2 could be detected in lamellar bodies and 
the intercellular space. By the release into the intracellular space within the epidermis 
hBD-2 can accumulate to high local concentrations (Oren et al., 2003). The concentration 
of hBD-2 in IL-1α stimulated keratinocytes were estimated in a range of 3.5-16 µM (Liu et 
al., 2002). Consistent with that, in psoriatic scales of human skin hBD-2 concentrations of 
2-10 µM were determined (Harder and Schröder, 2005).  
 
Like hBD-1, hBD-2 shows activity against gram-negative bacteria such as E. coli and 
P. aeruginosa. The concentration needed to kill 90% of all bacteria (LD 90) was estimated 
with 10 µg/ml. For killing of 90% of the yeast Candida albicans 25 µg/ml were needed 
and against the gram-positive pathogen S. aureus hBD-2 has only bacteriostatic effects at 
concentration greater than 100 µg/ml (Singh et al., 1998; Tomita et al., 2000; Liu et al., 
2002; Harder et al., 1997). Besides its antimicrobial activity, hBD-2 is a also 
chemoattractant for TNF-α-induced neutrophils and it can also recruit mast cells via a 
phospholipase C-dependent pathway (Niyonsaba et al., 2002). 
 
Human β-defensin-3 
The third member, hBD-3, was also isolated from psoriatic scales and the DEFB103A gene 
was cloned in 2001 from keratinocytes and lung epithelial cells (Harder et al., 2001; García 
et al., 2001; Jia et al., 2001). The highly basic AMP (pI 10.08) with 67 amino acids and a 
22 amino acid precursor is 43% identical to hBD-2 (García et al., 2001; Jia et al., 2001; 
Harder et al., 2001). DEFB103A is expressed in a variety of tissues, such as keratinocytes 
(García et al., 2001; Jia et al., 2001; Harder et al., 2001). TNF-α induces hDB-3 at a low 
level compared to the induction that IFN-γ achieves (Jia et al., 2001; García et al., 2001; 
Nomura et al., 2003). Interestingly, IL-1 and IL-6 lead to a further increased expression of 
DEFB103A during inflammation by modulating the transactivation of the EGF-receptor, 
even though these cytokines do not induce DEFB103A expression directly (Sørensen et al., 
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2005). DEFB103A gene expression is also induced by bacterial components (García et 
al., 2001; Harder et al., 2001). 
 
Table 1: Properties of skin derived AMPs 
 
Compared to hBD-1 and hBD-2, hBD-3 exhibits antimicrobial activity against S. aureus, 
including multiresistant strains (MRSA). Moreover, hBD-3 exhibits a broad spectrum of 
antimicrobial activity against many potentially pathogenic gram-negative and gram-
positive bacteria and fungi (García et al., 2001; Harder et al., 2001; Hoover et al., 2003; 
Maisetta et al., 2003; Sahly et al., 2003). HBD-3 kills S. aureus by perforation of the cell 
Properties of skin derived AMPs 
Name Antimicrobial activity Chemotactic 
properties 
Expression 
pattern 
Expression 
Stimuli Gram 
+ 
Gram 
- 
Fungi 
Human beta defensin family 
hBD-1 + + ? T-cells, DC 
constitutively 
expressed in 
skin 
Ca 2+ 
differentiation 
hBD-2 + + + T-cells, DC, MC 
induced upon 
inflammation 
IL-1α, IL-1β, 
TNF-α, IL-
22, bacterial 
components 
hBD-3 + + + T-cells, DC, 
monocytes 
induced upon 
inflammation 
TNF-α, IFNγ, 
bacterial 
components 
Ca2+ binding S100 family 
S100A7 + + ? T-cells, 
neutrophils 
induced upon 
inflammation 
TNF-α, IL-
1β, bacterial 
components 
S100A8 
S100A9 
+ + + 
neutrophils 
macrophages 
induced upon 
inflammation 
UVB, IL-1α, 
IL-6, IL-8, 
TNF-α, 
bacterial 
components 
S100A12 ? ? ? monocytes 
neutrophils 
induced upon 
inflammation 
TNF-α, LPS 
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wall. The plasma membrane is resolved within 30 minutes and bacteria are totaly lysed 
after 2h of contact. These effects remind of those seen when S. aureus is treated with 
penicillin (Giesbrecht et al., 1998; Harder et al., 2001). As shown by other members of the 
hBD family hBD-3 induces chemotaxis of immune cells. HBD-3 recruits monocytes and 
HEK 293 cells transfected with CCR6 (Wu et al., 2003). 
 
S100 PROTEIN FAMILY 
The S100 protein family is characterized by two calcium-binding sites that have helix-
loop-helix conformation. They have more functions than to act as antimicrobial peptide, 
for example they are involved in the regulation of Ca2+ homeostasis, cell growth, 
differentiation, and inflammatory response. This low molecular weight protein family is 
widely expressed in cells and tissues (Heizmann et al., 2002; Donato, 2003). Many of the 
21 members of the S100 family are encoded on chromosome 1q21 where also the 
epidermal differentiation complex (EDC) is located (Hardas et al., 1996; Wicki et al., 
1996; Volz et al., 1993). All S100A family members from S100A2 to S100A12 and 
S100A15 are expressed in the human epidermis or in cultured keratinocytes (Böni et al., 
1997; Xia et al., 1997; Broome et al., 2003; Wolf et al., 2003). 
 
S100A7 (Psoriasin) 
The 11 kDa protein psoriasin was originally discovered in psoriatic skin lesions as a new 
Ca2+-binding S100 protein of unknown biological function (Madsen et al., 1991). Psoriasin 
is distributed in the cytoplasm of keratinocytes. During differentiation it accumulates and 
localizes to the cell periphery of terminally differentiated keratinocytes (Broome et al., 
2003). Furthermore, sebocytes, the lipid-secreting cells of sebaceous glands, are also a 
source of psoriasin (Gläser et al., 2005). Psoriasin is secreted in vivo by the human body 
with different concentrations at different sites. The highest concentrations can be found at 
the forehead, armpit, palm, and at the sole of feet (Gläser et al., 2005). These are all areas 
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where high bacterial colonization is present. Further data indicates that the highly 
hydrophobic psoriasin is also stored in the lipid layer of healthy skin (Gläser et al., 2005). 
The proinflammatory cytokines TNF-α and IL-1β trigger the expression of psoriasin in 
human keratinocytes. In addition the contact of keratinocytes with E. coli induces the 
expression and secretion of psoriasin. Psoriasin shows antimicrobial activity against the 
gram-negative bacteria E. coli with LD 90 of 0.5 µM but against P. aeruginosa 
considerably less active. Similarly psoriasin has only a low activity with an LD 90 >30 µM 
against the gram-positive S. aureus (Gläser et al., 2005). This is in line with a minor 
activity against the commensal Staphylococcus epidermidis (Gläser et al., 2005). No 
morphological changes of E. coli's cell walls could be observed by electron microscopy 
after the treatment with psoriasin. This indicates that psoriasin acts differently from many 
cationic antimicrobial peptides (Zasloff, 2002). It is suggested that psoriasin kills E. coli by 
the sequestration of zinc (Gläser et al., 2005). 
 
S100A8 and S100A9 
S100A8 and S100A9 were found in the synovial fluid of patients with rheumatoid arthritis 
in 1987 (Odink et al., 1987). S100A8 and S100A9 form homo- as well as heterodimers and 
are expressed at very low levels in normal human epidermis (Teigelkamp et al., 1991). 
Both proteins are overexpressed in psoriasis and are present in the basal, granular and 
spinous layers (Broome et al., 2003). Additionally they are induced during inflammatory 
bowel disease (Lügering et al., 1995; Schmid et al., 1995). S100A8 and S100A9 expression 
is induced upon epidermal injury and UVB irradiation (Thorey et al., 2001). Keratinocytes 
overexpressing S100A8 and S100A9 show a reduction in cell division and enhanced 
expression of the differentiation markers filaggrin and involucrin. E. coli and 
P. aeruginosa as well as the cytokines IL-1α, IL-6, IL-8 and TNF-α trigger the expression 
of S100A8 and S100A9 in human keratinocytes (Abtin et al., 2010; Mørk et al., 2003; 
Nukui et al., 2008). The complex formed by S100A8 and S100A9 exhibits antimicrobial 
activity against gram-negative bacteria such as E. coli and also against gram-positive 
bacteria such as S. aureus and the commensal S. epidermidis (Brandtzaeg et al., 1995). 
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Furthermore activity against the fungus C. albicans was shown (Murthy et al., 1993). 
The sequestration of essential trace elements, as mentioned earlier for S100A7, such as 
zinc or manganese have been proposed as a potential mechanism of antimicrobial action 
(Murthy et al., 1993; Sohnle et al., 2000; Corbin et al., 2008). It has been demonstrated that 
S100A8 and S100A9 also can act as an intracellular antimicrobial peptide complex and by 
this can increase epithelial resistance against bacterial pathogens (Champaiboon et al., 
2009; Nisapakultorn et al., 2001b; a). When injected into mice, S100A8 stimulates the 
local accumulation of neutrophils and macrophages (Lau et al., 1995), whereas S100A9 
stimulates neutrophil adhesion (Newton and Hogg, 1998). 
 
S100A12 
S100A12 (calgranulin C, EN-RAGE) is a RAGE (Receptor for Advanced Glycation 
Endproducts) receptor ligand (Hofmann et al., 1999) and was first characterized in 1996 
(Wicki et al., 1996). S100A12 is overexpressed in many inflammatory diseases (Yang et 
al., 2001; Rouleau et al., 2003; Foell et al., 2003a; b), for example in psoriasis 
(Mirmohammadsadegh et al., 2000; Semprini et al., 2002), where it accumulates in the 
suprabasal epidermal layers (Mirmohammadsadegh et al., 2000; Semprini et al., 2002). 
LPS as well as TNF-α induce the expression of S100A12 mRNA in monocytes (Yang et 
al., 2001). It was shown that S100A12 has activity against the parasite Brugia malayi. 
S100A12 inhibits the movement of the worms and affects microfilariae (an early stage of 
nematode development) motility (Gottsch et al., 1999). Furthermore S100A12, like 
S100A8 and S100A9, induces neutrophil adhesion and also monocyte migration (Rouleau 
et al., 2003). 
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CYTOKINES AND THE SKIN BARRIER 
Cytokines are small proteins, which are important in cell signaling and in regulating cell 
growth and differentiation. Cells release them and they affect other cells by acting through 
receptors on the cell surface. The large group of cytokines includes chemokines, 
interferons, interleukins, and tumor necrosis factors but not hormones and growth factors. 
Keratinocytes and other skin resident cells produce cytokines that are responsible for the 
control of cellular communication. For example cytokines influence keratinocyte 
proliferation and differentiation, at least in part by modulating the gene expression 
program in these cells. One consequence is the expressional control of other cytokines 
resulting in a feedback loop and complex network of signaling molecules that affect the 
physiology of keratinocytes and the quality of the skin barrier. Deregulated cytokine 
expression can thus contribute to dysfunctions of the epidermal barrier as it is observed in 
many diseases, including atopic dermatitis (AD) and psoriasis. 
 
CYTOKINE FAMILIES 
Cytokines and their receptors can be classified based on the three-dimensional structure of 
the receptors. This classification results in six groups: 1. Interleukin type I cytokine 
receptors with a conserved WSXWS amino acid motif in the extracellular domain. 2. 
Interleukin type II cytokine receptors, which are similar to type I receptors but lack this 
conserved motif. 3. The Immunoglobulin (Ig) superfamily sharing structural homology 
with immunoglobulin domains in their extracellular part. 4. The tumor necrosis factor 
receptor (TNFR) family sharing a cysteine-rich extracellular cytokine-binding domain. 5. 
The IL-17 family of cytokine receptors sharing only little homology with the receptors of 
the other cytokine families. Finally within group six there are chemokine receptors that 
couple to G proteins. In Figure 3 the in the following mentioned cytokine receptor families 
are summarized together with their signaling pathways. Cytokines belonging to the above-
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mentioned cytokine families, which are reported to have an impact on skin barrier 
function, will be described. 
 
Figure 3: Cytokine receptor complexes, their ligand families and corresponding signaling pathways involved in 
skin barrier regulation. 
The cytokine receptor families are grouped according to the three-dimensional structure of their receptors. The receptors of 
the interleukin type I and interleukin type II families possess extracellular fibronectin like domains. These two families differ 
only in the WSXWS motif present in the type I but not type II receptors. The tumor necrosis factor receptor (TNFR) family 
has cysteine-rich motifs in their extracellular regions able to bind ligands. The immunoglobulin (Ig) superfamily shares 
homology with immunoglobolin domains in their extracellular regions structural. 
 
Interleukin Type I 
The interleukin type I cytokine receptors can be further subdivided into five sub-groups of 
which three are relevant. The cytokines mentioned in the following text can be divided into 
the following sub-groups. The γ-chain containing IL-2 family receptor for the cytokine 
thymic stromal lymphopoietin (TSLP) (Liao et al., 2011); the IL-6 or gp130 family, a sub-
group that includes gp130 in their receptor complexes with the members IL-31 and 
Oncostatin M (OSM) (Garbers et al., 2012). The extracellular part of the interleukin type I 
receptor family consist of fibronectin like domains with a WSXWS domain specific for 
this type of receptor family. Signaling of these receptors through their intracellular parts 
activates the JAK / STAT, MAP kinase and PI3K / AKT pathways (Figure 3).  
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The IL-2 Family of Cytokines 
The IL-2 family contains six members, IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. The 
members of this family share the IL-2 receptor common γ-chain (CD132). In the following 
briefly the IL-7-like cytokine thymic stromal lymphopoietin (TSLP) is discussed (Ziegler 
and Artis, 2010). TSLP binds to a heterodimeric receptor complex consisting of the IL-7 
receptor alpha and the thymic stromal lymphopoietin receptor (TSLPR). The TSLPR is 
most closely related to the common γ-chain, which binds TSLP only with low affinity 
(Ziegler and Artis, 2010). 
 
TSLP 
Thymic stromal lymphopoietin (TSLP) is increased in AD skin lesions compared to 
healthy controls (Alysandratos et al., 2010). Serum levels of TSLP were also elevated in 
children suffering from AD compared to controls (Lee et al., 2010). Furthermore an 
association between genetic variants in TSLP and AD was found (Gao et al., 2010). A 
broad variety of cytokines including, IL-1α IL-4, IL-13, IL-31, and TNF-α, were shown to 
induce the expression and release of TSLP from keratinocytes (Bogiatzi et al., 2007; Danso 
et al., 2014). TSLP release from epithelia cells was also shown upon stimulation with 
microbial products, such as flagellin and physical injury (Le et al., 2011; Allakhverdi et al., 
2007). Furthermore infections with S.aureus triggers Th2 inflammation in keratinocytes 
via TSLP (Vu et al., 2010). The released TSLP activates dendritic cells leading to 
production of proallergic cytokines (Soumelis et al., 2002). In addition TSLP activated 
dendritic cells prime naïve Th-cells to produce IL-5, IL-13 and TNF-α. Furthermore they 
also inhibit the expression of IL-10 and IFN-γ (Watanabe et al., 2004; Soumelis et al., 
2002). Beside all these proinflammatory properties TSLP also induces itch by acting 
directly on a subset of sensory neurons (Wilson et al., 2013b).  
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The IL-6 Family of Cytokines 
In the following the IL-6 family cytokines IL-31 and OSM are briefly discussed. Beyond 
these two the IL-6 family contains more members and all activate the signal transducing 
receptor protein, glycoprotein 130 (gp130), except for IL-31. The receptor heterodimer for 
IL-31 consists of a unique gp130-like receptor chain IL-31RA, and the receptor subunit 
Oncostatin M receptor beta (OSMRβ). 
 
IL-31 and OSM 
AD patients show significant higher levels of IL-31 in serum and increased IL31 mRNA 
levels in lesional skin samples in contrast to healthy individuals (Kim et al., 2011). These 
higher levels are correlated with serum IgE, disease severity, and subjective itch intensity 
(Schmuth et al., 2007; Kim et al., 2011; Nobbe et al., 2012; Raap et al., 2008; Neis et al., 
2006). As described above, IL-31 signals via its heterodimeric receptor complex composed 
of the IL-31RA and the OSMRβ (Dillon et al., 2004). IL-31 interferes with keratinocyte 
differentiation in organotypic 3D cell culture models, where the keratinocytes at the air-
liquid interphase are able to differentiate into a skin-like structure. Treatment of these 
models with IL-31 leads to a reduced epidermal thickness, disturbed epidermal 
constitution, altered alignment of the SB and poor development of the SG. The observed 
differentiation defect is associated with a profound suppression of terminal differentiation 
markers, including filaggrin (FLG), an essential factor for skin barrier formation, and a 
reduced lipid envelope (Cornelissen et al., 2012b). Moreover transgenic mice 
overexpressing IL-31 develop severe pruritus, alopecia (hair loss) and skin lesions (Dillon 
et al., 2004). IL-31 may also play a role in the sensation of itch because several itch-
associated skin diseases like prurigo nodularis (Sonkoly et al., 2006), chronic spontaneous 
urticaria (Raap et al., 2010), and allergic contact dermatitis (Neis et al., 2006) exhibit high 
protein levels in blood serum and skin mRNA levels of IL-31. Treatment of Nc / Nga mice 
(a model for AD) with anti-IL-31 antibodies resulted in a reduction in scratching behavior 
(Takaoka et al., 2006; Grimstad et al., 2009) Dorsal root ganglia that are meant to be 
responsible for the sensation of itch express the IL-31 receptor and their unmyelinated 
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nerve fibers might be directly stimulated by IL-31. It might also be possible that IL-31 
triggers the expression of pruritic factors, which subsequently activate the nerve fibers 
leading to the sensation of itch (Cornelissen et al., 2012a). As this is mediated by neurons, 
the regulation of pruritus by IL-31 might be completely unrelated to its suppression of 
keratinocyte differentiation (Cornelissen et al., 2012a).  
 
Both OSM production and OSM receptor expression are enhanced in inflammatory skin 
diseases. OSM is a potent inducer of keratinocyte migration and triggers hyperplasia of 
reconstituted human epidermis (Boniface et al., 2007). OSM suppresses the expression of 
the ‘‘classical’’ epidermal differentiation markers (e.g filaggrin) causing a reduction of 
cornified cells in reconstituted human epidermis (Gazel et al., 2006). Cells as well as skin 
models show similar phenotypes when treated with either IL-31 or OSM. This could be 
due to the similarity of both receptor complexes. So far IL-31 is the only cytokine of the 
IL-6 family that does not signal through a receptor complex that contains gp130, which 
makes it a unique member within this family. Thus to understand IL-31 signaling the 
expression pattern of the OSMRβ needs to be considered.  
 
High serum levels of IL-31 in AD patients, impaired differentiation in organotypic models 
(that do not include inflammatory cells or factors besides the ones that may be produced by 
keratinocytes), and the increased scratching behavior in AD mice provoked the conclusion 
that high IL-31 expression is one of the causes rather than only a symptom of AD. This 
suggests that anti-IL-31 treatment, either by blocking the IL-31 receptor complex or by 
reducing IL-31 cytokine levels, may be beneficial for patients (Hanel et al., 2013). 
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Interleukin Type II 
Type II cytokine receptors are divided into three sub-groups, i.e. the IL-10 family and the 
type I and type II interferon families. All three sub-groups have been found to affect the 
proliferation and differentiation of keratinocytes. In particular the IL-10 family has various 
effects on the skin (Zdanov, 2010). Such as the Interleukin type I cytokine receptors, the 
type II receptors use the same signaling pathways ((MAP kinase, JAK / STAT, and PI3K / 
AKT) (Figure 3)). 
 
IL-10 Family 
IL-20 
The expression of the IL20 gene is also increased in inflammatory skin diseases like AD or 
psoriasis (Kunz et al., 2006) and IL20 mRNA is upregulated in lesional compared to non-
lesional psoriatic skin (Otkjaer et al., 2005). IL-20 induces proliferation of keratinocytes in 
monolayer culture, even if a neutralizing antibody against EGFR blocks autocrine growth. 
In line with these results, IL-20 triggers acanthosis or hyperplasia in stratified epidermal 
culture systems and epidermal thickening in the early cell layers in a dose dependent 
manner (Sa et al., 2007). In organotypic 3D co-cultures of keratinocytes with fibroblasts 
IL-31 is able to promote the expression of IL20 and IL24, suggesting that these two 
cytokines are downstream effectors of IL-31. Indeed, IL-20 and IL-24 possess a small 
inhibitory effect on the differentiation within the 3D model. This phenotype is also 
characterized by a reduced expression of filaggrin and keratin 10. It is worth mentioning 
that these effects are relatively minor compared to IL-31, indicating that IL-31 induces 
additional mediators that control keratinocyte differentiation (Cornelissen et al., 2012b). 
 
Overexpression of IL-20 in transgenic mice causes neonatal lethality with skin 
abnormalities including aberrant epidermal expression of several keratins indicating a 
prominent role of IL-20 in epidermal development during embryogenesis (Blumberg et al., 
2001). Histological analyses of the skin of different IL-20 transgenic mice display a 
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thickened epidermis, hyperkeratosis, a compact SC and the cells of this layer express 
differentiation and proliferation markers that are normally confined to the basal and 
suprabasal layers of the skin. Overexpressing IL-20 in other tissues also causes these 
changes in the skin, indicating that circulating and epidermis infiltrating IL-20 is most 
likely responsible for the observed phenotype (Rich and Kupper, 2001). 
 
IL-24 
Similar to IL-20, IL-24 expression is increased in inflammatory skin diseases like AD or 
psoriasis (Kunz et al., 2006) and IL-24 induces, as well as the other IL-10 family members 
IL-19 and IL-20, the proliferation of keratinocytes in monolayer cultures. Like IL-20, IL-
24 promotes acanthosis / hyperplasia in a reconstituted human epidermis culture system 
and epidermal thickening in the early cell layers in a dose dependent manner. IL-24 
decreases keratin 10 (KRT10) mRNA expression (Boniface et al., 2005) while it increases 
keratin 16 (KRT16) mRNA (Sa et al., 2007). Keratin 16 is upregulated in the suprabasal 
layers of interfollicular epidermis showing hyperproliferation and abnormal differentiation 
and thus also serves as a psoriasis marker protein (Bhawan et al., 2004). IL-24 is able to 
inhibit TGFα-induced migration of keratinocytes in an in vitro model of wound repair and 
interferes with TGFα-mediated proliferation of keratinocytes (Poindexter et al., 2010). In 
organotypic co-cultures with fibroblasts, IL-24 together with IL-20 impairs differentiation 
and reduces the expression of FLG and KRT10 (Cornelissen et al., 2012b). IL-24 leads to 
an increase of epidermal thickness in transgenic mice (He and Liang, 2010). Together 
these findings document that IL-24 function in normal skin is distinct from skin with an 
inflammatory response. In the former, IL-24 increases the proliferation and impairs normal 
differentiation whereas in inflamed skin both proliferation and migration of keratinocytes 
is inhibited. This suggests that the consequences of IL-24 are modulated or negated by 
other cytokines / signals present during inflammation. It would be interesting to define the 
nature of these factors that crosstalk with IL-24 signaling.  
 
INTRODUCTION  30
These observations indicate a number of different roles for the cytokines of the IL-10 
family (with the exception of IL-10 itself, whose function is rather distinct in comparison 
to the other family members) in regulating keratinocyte proliferation and differentiation in 
the epidermal layer. IL19, IL20 and IL24 are clustered together with IL10 in the IL10 gene 
cluster on chromosome 1q32 whereas IL22 is located on chromosome 12q14 (Blumberg et 
al., 2001; Pestka et al., 2004). This clustering of the genes and the fact that IL-19, IL-20 
and IL-24 signal via the same receptor components (IL-20R1, IL-20R2, IL-22R1) and thus 
are able to activate the same signaling pathways may be one reason for these overlapping 
but not identical phenotypes in response to these cytokines. It seems that all these 
cytokines have a role in regulating the skin barrier by controlling keratinocyte proliferation 
and migration as well as abrogating the expression of genes that encode components of the 
skin barrier (Hanel et al., 2013).  
 
Interferons 
The family of interferons can be subdivided into two groups. Group I interferons, binding 
to IFNA receptors (IFNAR), include IFN-α, IFN-β and IFN-ω. IFN-γ is the only member 
of the group II interferons, which interact with the IFNG receptors (IFNGR). 
 
IFN-α and IFN-γ 
IFNG expression is increased in inflammatory skin disease like AD or psoriasis (Wolk et 
al., 2004; Kunz et al., 2006). In these diseases higher levels of IFN-α and IFN-γ can alter 
the response to different cytokines by regulating the expression of their corresponding 
receptors. It was shown that IFN-γ enhances the expression of the IL-31 receptor (Feld et 
al., 2010; Heise et al., 2009) and of the OSM receptor (Dambacher et al., 2007), while 
reducing IL-4 receptor expression (Albanesi et al., 2000), whereas IFN-α enhances the 
expression of the IL-22 receptor (Tohyama et al., 2012). IFN-α as well as IFN-γ have a 
modulatory effect on the expression of the integrins α3, α6 and β1. IFN-α treatment has an 
inhibitory effect on integrin α6 expression in basal cells of reconstructed skin (Tenaud et 
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al., 2002). The integrins α6 and β4 are main components of the hemidesmosomes, which 
are essential protein complexes that mediate the firm attachment of epithelial cells to the 
underlying basement membranes (Litjens et al., 2006). Mice with a conditional ablation of 
integrin α6 in the epidermis present skin fragility and inflammation (Niculescu et al., 
2011), the latter probably as a consequence of impaired barrier formation. Moreover α3β1 
integrins play crucial roles in the organization of epithelial and endothelial tissues by 
exerting functions related to cell adhesion and migration (Tsuji, 2004). In contrast to the 
decreased epidermis-dermis interaction, the levels of transcripts for acid sphingomyelinase 
(SMase) and glucocerebrosidase (GCase), both enzymes play important roles in ceramide 
synthesis, are stimulated in response to IFN-γ (Sawada et al., 2012). SMase hydrolyses 
sphingomyelin thereby producing ceramides 2 and 5 (Uchida et al., 2000), whereas GCase 
degrades glucosylceramide to produce the ceramides 1 to 7 (Hamanaka et al., 2002). 
Ceramides are an integral part of the lipid envelope accounting for 30% - 40% of stratum 
corneum lipids by weight. In combination with cholesterol and free fatty acids (FA), 
ceramides form the extracellular lamellar membrane structures. This subserves the 
permeability barrier and is important to prevent water loss due to evaporation (Madison, 
2003). Thus through activation of the expression of SMase and GCase, IFN-γ enhances 
ceramide synthesis and consequently strengthens the lipid envelope. Consistent with these 
findings is that IFN-γ suppresses TEWL (Hatano et al., 2005).  
 
In conclusion, IFNs seem to play a role in maintaining the barrier function of the skin by 
regulating receptors important for cytokine signaling, including the IL-4 and IL-31 
receptors. Cytokines belonging to these receptors have a tremendous impact on the 
formation of the skin barrier (see above). Furthermore IFNs seem to directly influence the 
detachment of keratinocytes from the basal membrane, an essential step in the 
differentiation process from basal to primary differentiating suprabasal cells. Additionally 
IFNs are involved in ceramide synthesis and therefore impact the formation of the lipid 
envelope and thus are able to regulate TEWL.  
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Ig superfamily (receptors with extracellular immunoglobulin (Ig)-like 
domains) 
The IL-1 family of cytokines includes a growing number of members that play important 
roles in immune regulation and inflammatory processes (summarized in (Barksby et al., 
2007)). In the following the functions of those family members, i.e. IL-1α and IL-1β, 
which have been analyzed in combination with epidermal differentiation and skin diseases 
are addressed. 
 
IL-1α and IL-1β 
The cutaneous expression of IL1A transcripts is reduced in inflammatory skin diseases like 
psoriasis or AD whereas no significant changes are seen for IL1B (Wolk et al., 2004). In 
contrast an increase of secreted IL-1α in lesional skin of psoriasis patients was observed 
(Portugal-Cohen et al., 2012). After acute permeability barrier disruption, an increase in 
the epidermal expression of IL-1α and IL-1β occurs, which might have a protective 
function (Wood et al., 1992). Indeed stimulating keratinocytes with IL-1α enhances the 
synthesis of barrier lipids in monolayer cell culture models (Barland et al., 2004). In 
contrast O’Shaughnessy and colleagues found that IL-1α leads to hyperkeratosis without 
increased lipid synthesis and causes a reduction of keratin 10 and involucrin expression. 
Moreover IL-1α promotes the expression of the fatty acid desaturase 2 in organotypic 3D 
cultures (O'Shaughnessy et al., 2010). These contrasting findings regarding the influence of 
IL-1α on lipid synthesis in particular could be due to differences in the experimental setup. 
Barland and colleagues used calcium differentiated keratinocytes in a monolayer culture 
(Barland et al., 2004), while OShaughnessy et al. treated organotypic 3D cultures with IL-
1α (O'Shaughnessy et al., 2010). 3D co-cultures with fibroblasts serve as a more 
physiological model for epidermal development and homeostasis, in which the Ca2+ 
gradient develops in the epidermal layer comparably to normal skin. Moreover the 
fibroblasts provide physiologically relevant cytokines and growth factors. In contrast Ca2+-
induced differentiation of a monolayer culture results in a highly simplified version of the 
differentiation program. This might explain the differences observed in the two models in 
response to IL1-α. Although this seems an obvious explanation, it should be noted that 
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explicit studies addressing the differences of keratinocyte differentiation between the 3D 
co-culture model and a monolayer culture treated with Ca2+ are missing. In other words it 
remains open to what extent these different models are comparable. Nevertheless it will be 
important to define the role of IL-1α in more detail, as this important cytokine is likely to 
be involved in keratinocyte differentiation. 
 
The intra-cutaneous administration of IL-1α was able to improve barrier function in mice 
by enhancing the lipid synthesis and the lamellar body formation (Barland et al., 2004). In 
another study, IL-1α injected into mice led to an increased barrier recovery after 
perturbation and IL-1α stimulation restored epidermal permeability and the antimicrobial 
barrier that were compromised by topical application of tacrolimus, an immunosuppressive 
drug (Jung et al., 2011). IL-1α upregulates the expression of genes associated with cell 
adhesion, proliferation, and epidermal differentiation (Yano et al., 2008). Conversely, 
transgenic mice that overexpress IL-1α in basal keratinocytes under the control of the K14 
promoter develop spontaneous inflammatory skin lesions, as well as dermal neutrophil 
infiltration even in non-lesional skin (Groves et al., 1995). In all epithelial cells the IL-1α 
precursor is constitutively expressed, translocates to the nucleus and can modulate gene 
transcription and thus modifies cell behavior and cellular differentiation (Dinarello, 2009). 
Overexpressing this biological active precursor in keratinocytes has distinct consequences 
to the skin barrier in comparison to injecting a biologically active IL-1α that binds to its 
cell surface receptor and induces intracellular signaling. IL-1α signaling attracts 
lymphocytes and neutrophils via the expression of CCL20 in keratinocytes (Yano et al., 
2008). Mice with a knockout of the IL-1 receptor type 1 develop a more profound barrier 
deficit than age-matched wild-types and an increase in IL-1α protein expression in the skin 
after acute permeability barrier perturbation. IL-1β treatment leads to an increased 
expression of the main thigh junction proteins occludin and claudin-1 at early time points 
after treatment. Furthermore ZO-1, which connects tight junctions with the cytoskeleton, 
was also up regulated in organotypic 3D models at early time points after treatment. In 
contrast to this early response to the IL-1β treatment, after 96 h of stimulation the 
expression of all these proteins is decreased. In line with the altered expression of these 
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structural proteins also a functional effect could be observed. The treatment with IL-1β 
leads to an increased transepithelial resistance, indicating an increased barrier of calcium 
differentiated keratinocytes as a consequence of the early response and a decreased 
resistance at later stages (Kirschner et al., 2009). 
 
It appears that IL-1α and IL-1β have profound effects on epidermal differentiation that 
need to be tightly controlled under physiological conditions. They are able to strengthen 
the epidermal barrier via influencing the mechanical attachment of cells and the formation 
of the lipid envelope. This might be highly relevant in a response to e.g. mechanical injury 
of the skin and wound repair. Nevertheless a deregulated expression of IL-1α seems to 
promote an inflammatory skin phenotype e.g. manifested by attraction of inflammatory 
cells. Together it seems worth proposing that the role of IL-1α and β in skin physiology 
and pathology needs to be studied in greater detail, for example to answer the question 
whether deregulated IL-1 expression occurs in skin diseases and if this might contribute to 
disease symptoms like barrier disruption. 
 
CONCLUDING REMARKS 
The various cytokines act at multiple levels to control barrier formation, like the 
cornification process (e.g. IL-31), the composition of the lipid envelope (e.g. IFN-γ) and 
cell-cell adhesion (e.g. IL-1α). Cytokines and their targets in the formation of the skin 
barrier, even those that were not mentioned in the text before, are summarized in Figure 4. 
Many discussed cytokines alter the expression of structurally important proteins involved 
in the formation of the cornified envelope, including loricrin and profilaggrin. Some also 
prevent the development or maintenance of tight junctions, corneodesmosomes and 
hemidesmosomes, thereby affecting the interaction of terminally differentiated cells in the 
cornified envelope or the basal cell layer. Moreover cytokines control the expression of 
genes that encode enzymes key to process the proteins and lipids associated with terminal 
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differentiation. Because these processes are highly balanced it is not surprising that 
many cytokines provoke a weakening of the barrier, albeit their effects are mediated by 
different components. These contribute to inefficient barrier formation, beginning with 
effects on early differentiation processes to the disturbance of terminal events that define 
the barrier proper. In addition to these “antagonistic” cytokines for barrier formation, 
others cytokines appear to be important for the efficient repair of barrier activity. This 
indicates that the interaction of different cytokines will need to be addressed to understand 
how cytokine balance is relevant for the protective function of the skin.  
 
 
Figure 4: Regulatory effects of the cytokines on the barrier formation. 
This figure illustrates the relevant effects of cytokines on the formation of the skin barrier and selected targets in the 
differentiation process documented either in cell culture or in animal studies. Arrows indicate the consequences on these 
processes. (é) Indicates that the cytokine enhances or promotes the target process; (ê) indicates that the cytokine 
downregulates or inhibits the target process. 
It should be noted that in most cases it is still unclear what the mechanistic base is for these 
effects. This may be at least in part due to the difficulties in analyzing individual steps 
during the differentiation process, as this is only efficiently occurring in vivo or in 3D 
organotypic cultures. Moreover the terminal differentiation events, which result in the 
cornified envelope, are challenging to study at the cellular level beyond documenting 
protein expression by for example immuno-histochemical analyses because the cells do no 
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longer proliferate and cannot easily be separated from earlier differentiation stages. As a 
consequence, in most situations it is not clear how a specific cytokine controls the 
expression of genes relevant for the differentiation process. Together the studies that are 
presently available do not allow precise conclusions about how certain cytokines affect 
barrier formation. In particular it is typically not known whether a cytokine controls the 
expression of a relevant gene directly or whether these are secondary effects.  
 
The mechanistic studies are further complicated, by many additional cells beyond 
keratinocytes that infiltrate the epidermis of animals. Many of these are immune cells that 
respond to different cytokines and also produce cytokine cocktails making the analysis of 
individual cytokines complex. Nevertheless it is striking that the majority of the cytokines, 
which disrupt the barrier function of the epidermis in model systems, are also deregulated 
in skin diseases, including AD and psoriasis. Moreover the overexpression of these 
cytokines typically correlates with disease severity. An additional important level of 
complexity is given by the fact that the disruption of the skin barrier facilitates the invasion 
of pathogens and allergens. In turn this contributes to local inflammatory immune 
responses. In other words, deregulated cytokine expression in the skin can weaken barrier 
function and thus aggravate the inflammatory response, thereby establishing a viscous 
circle. Thus it is quite obvious that the management of cytokine expression and activity is 
important to control and ameliorate disease development in the skin.  
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AIM OF THIS WORK 
Patients suffering from inflammatory skin diseases such as AD have profound barrier 
defects (Bouwstra and Ponec, 2006). These defects in the barrier formation lead to 
increased penetration of the skin by allergens and pathogens, thereby aggravating disease 
symptoms. In line with these observations, around 90% of all AD patients suffer from 
bacterial super infections (Schittek, 2011). In contrast to the pathological appearance, the 
relevant pathogenic mechanism leading to AD remains largely unclear. One hint might be, 
that AD patients show significantly higher levels of IL-31 in serum and increased IL31 
mRNA levels in lesional skin samples in contrast to healthy individuals (Kim et al., 2011). 
These higher levels correlate with disease severity and subjective itch intensity (Schmuth 
et al., 2007; Kim et al., 2011; Nobbe et al., 2012; Raap et al., 2008; Neis et al., 2006). 
Previous work has shown that IL-31 is an important regulator of keratinocyte 
differentiation (Cornelissen et al., 2012a). 
 
Therefore the aim of this thesis was to investigate the role of IL-31 on skin barrier function 
in in vitro and in vivo models. To study this, expression arrays were used to identify genes, 
which are differentially expressed during the organotypic differentiation of keratinocytes 
of untreated and IL-31 treated cells. In vitro models including monolayer cultures, 3-
dimensional organotypic skin equivalents and, a cell-sorted skin equivalent (CeSSE) in the 
mouse were used. Moreover a second part of this thesis was to identify IL-31 signaling 
pathways as well as factors induced by IL-31 and their functional consequences. 
Furthermore a part of this work was to identify the potential role of IL-31 in healthy human 
skin. 
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IL-31 CONTROLS THE EXPRESSION OF GENES ASSOCIATED 
WITH THE MECHANICAL BARRIER 
Previous studies of our group in cooperation with the Institute of Dermatology and 
Allergology revealed that IL-31 is an important regulator of keratinocyte differentiation 
(Cornelissen et al., 2012b). However there are no reports describing the influence of IL-31 
on the skin barrier formation. Due to this fact it was of general interest to identify this 
influence and furthermore to recognize downstream signaling pathways. To understand the 
role of IL-31 for the formation of the skin barrier, human recombinant (rh) IL-31 was 
applied to organotypic 3D models of HaCaT-IL31RA cells and gene expression was 
analyzed using Affymetrix gene arrays after 2, 8, 24 or 48 h. These organotypic 3D models 
consist of two different cell types. The basal, dermal part of these skin models is 
constructed with human dermal fibroblasts suspended in bovine collagen. On top of this, 
the epidermal layer is seeded by HaCaT keratinocytes expressing the IL-31 receptor alpha 
(RA) under the control of a doxycycline inducible expression vector (Cornelissen et al., 
2012b; Neis et al., 2010). These layers are lifted to and cultivated at the air-liquid 
interphase to induce keratinocyte differentiation. (For a better understanding, the models 
are lifted to the air-liquid interphase two days after seeding the keratinocytes and for all 
following experiments day 0 is defined as the day when the models were lifted to the air-
liquid interphase.) IL-31 treatment resulted in altered expression of approximately 570 
genes including a broad range of genes encoding for example differentiation-associated 
structural proteins (Figure 5 A). Genes encoding desmosomal proteins and filaggrin 
processing enzymes were repressed (Figure 5 B). Most notably the genes encoding 
desmoglein 1 and 4 (DSG1 and 4), but also desmocollin 1 and 2 (DSC1 and 2) and 
corneodesmosin (CDSN) were down regulated. DSG1 and DSC1 are essential components 
of corneodesmosome and are targets of proteases important for skin desquamation (Hoste 
et al., 2011; Amagai and Stanley, 2012; Ishida-Yamamoto et al., 2011). CDSN is 
covalently linked to the cornified envelope (CE) (Jonca et al., 2002). Also the expression 
of the genes encoding caspase-14 (CASP14) and kalikrein-like peptidase 7 (KLK7), two 
important proteases involved in the processing of filaggrin during keratinocyte 
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differentiation were repressed (Hoste et al., 2011; Hvid et al., 2011; Yamamoto et al., 
2011) (Figure 5 B).  
 
 
Figure 5: IL-31 deregulates the expression of genes associated with the mechanical skin barrier. 
A and B. HaCaT-IL31RA organotypic 3D models were stimulated with or without 100 ng/ml rhIL-31 for 2, 8, 24 or 48 h. 
Gene expression was analyzed using Affymetrix exon arrays. Indicated are the fold changes relative to the untreated 
control. C. qRT-PCR analysis of the indicated genes in HaCaT-IL31RA monolayer cells stimulated with 100 ng/ml rhIL-31 
for the indicated time, mean values ± SD, n = 3. D and E. qRT-PCR analysis of a 10 day HaCaT-IL31RA 3D organotypic 
skin model, models were treated every second day with 100 ng/ml rhIL-31, mean values ± SD, n = 3. P-values were 
calculated using Student’s t-test (* p<0.05; ** p<0.01; *** p<0.001). 
A first confirmation of the array data was done in HaCaT-IL31RA monolayer cultures 
treated with IL-31 for up to 72 h using qRT-PCR (Figure 5 C). In this experimental setting 
downregulation of the genes encoding DSG1, DSG4, DSC1, CASP14 and KLK7 could be 
observed. However DSC2 gene expression was upregulated upon IL-31 stimulation (Figure 
5 C) and DSG1 gene expression returned to initial levels after 72 h IL-31 treatment (Figure 
5 C), which was not seen in the array data (Figure 5 B). Furthermore, the expressions of 
these genes was analyzed by qRT-PCR in HaCaT-IL31RA organotypic skin equivalents, 
differentiated and stimulated every second day with IL-31 for 10 days. In these skin 
equivalents DSG1, DSG4, DSC1, DSC2, CDSN, CASP14 and KLK7 were significantly 
downregulated upon IL-31 treatment (Figure 5 D). In a similar experimental setting it was 
tested if the gene expression of tight junction proteins was also affected by IL-31. Unlike 
genes expressing desmosomal proteins, tight junction genes were not deregulated or to a 
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minor extend such as both cingulin family members CGN (cingulin) and CGNL 
(cingulin-like 1) (Figure 5 E). 
 
IL-31 WEAKENS THE SKIN BARRIER 
The reduced expression of genes encoding proteins relevant for the mechanical barrier in 
response to IL-31, as shown before, prompted to assess the integrity of the epidermal 
barrier. In order to determine the impact of IL-31 on desmosomal maturation and the 
formation of the cornified envelope, 10-day-old HaCaT-IL31RA organotypic skin models 
either treated with IL-31 every second day or untreated, were incubated with biotin, either 
applied from the apical or the basolateral side of the model (Figure 6 A). The application 
from the apical side should test the formation of the CE. Application from the basolateral 
side was for testing desmosome maturation. In the IL-31 treated organotypic model 
apically applied biotin (arrows) penetrated into the upper layer of the CE (Figure 6 A, 
upper panel). When biotin was applied from the basolateral side, biotin accumulated 
between the keratinocytes and fibroblasts in the untreated control. In the IL-31 treated 
model biotin did not accumulate at the basal membrane but it was also found in the CE 
(Figure 6 A, lower panel). Moreover fluorescently labeled biotin added to the dermal side 
of a 10-day-old organotypic HaCaT-IL31RA model penetrated through all nucleated 
epidermal layers and accumulated in the cornified envelope only when the model was 
stimulated with IL-31 (Figure 6 B). To further evaluate these findings and to mimic a more 
in vivo situation, a HaCaT-IL31RA organotypic 3D model was incubated with 
fluorescently labeled recombinant timothy grass pollen major allergen (phl p1) (Suphioglu, 
2000). Immunofluorescence imaging showed that the allergen stayed on top of the model 
and did not penetrate the control organotypic epidermis, whereas it was enriched in deeper 
layers upon IL-31 treatment (Figure 6 C). 
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Figure 6: IL-31 weakens the skin barrier.  
A. HaCaT-IL31RA organotypic skin equivalents were treated with or without 100 ng/ml rhIL-31 every second day. The 
models were incubated with biotin applied from the apical (upper panel) or basolateral side (lower panel) for 60 min at day 
10. Sections were analyzed by immunohistochemistry. Scale bar lines 1 and 3, 100 µm, scale bar lines 2 and 4, 200 µm. B. 
HaCaT-IL31RA organotypic skin equivalents (stimulated and cultivated as in A) were incubated at day 10 basolaterally with 
labeled biotin (green) for 60 min and histological sections were stained for DNA with DAPI (blue). Scale bar 100 µm C. 7-
day-old HaCaT-IL31RA 3D models (stimulated and cultivated as in A). Fluorescently labeled recombinant timothy grass 
pollen major allergen (phl p1) was applied topically for 45 min. Histological sections were HE stained (line 2 and 4) and the 
location of phl p1 (green) was determined by fluorescence microscopy and DNA was stained with DAPI (blue, line 1 and 3). 
Scale bar HE stain 200 µm, scale bar fluorescence microscopy 100 µm. D. 7-day-old HaCaT-IL31RA 3D models were 
treated with 0.2% SDS and/or 100 ng/ ml rhIL-31 for 40 min. IL-1α release was measured by ELISA and IL1A mRNA 
expression was measured by qRT-PCR after 24 h. Mean values of 2 experiments are displayed. n.d., not determinable. 
The data is part of Hänel et al., manuscript submitted. Panel C and D were performed in collaboration with and by Philipp M. 
Amann (Department of Dermatology and Allergology, University Hospital Aachen). 
Besides allergens and pathogens several irritants also affect the human skin. Upon 
treatment with irritants human keratinocytes are able to release inflammatory mediators in 
vitro and in vivo (Perkins et al., 1999; Roguet, 1999). It was also shown that the cytokine 
IL-1α is produced and released in a concentration and time-dependent manner after 
keratinocytes were treated with irritants such as sodium dodecyl sulfate (SDS) or UVB 
light, even at levels which are not cell cytotoxic (Cohen et al., 1991). Further publications 
have elaborated that IL-1α is a good marker for induced cell damage (Bernhofer et al., 
1999b; a; Perkins et al., 1999; Mühlen et al., 2004). It was tested if IL-31 alone or in 
combination with SDS triggers an irritating feature. For this purpose IL-31, SDS or both 
together were applied apically to fully developed 7-day-old HaCaT-IL31RA organotypic 
skin models, the applied substances were washed away after 40 min, and IL1A gene 
expression and IL-1α release were measured after 24 h. Topical treatment with the irritant 
SDS promoted expression and release of IL-1α in an organotypic model pretreated with IL-
31 compared to untreated controls (Figure 6 D). Furthermore the combined treatment of 
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IL-31 and SDS resulted in a higher IL-1α secretion and IL1A gene expression than the 
sum of the individual treatments. Moreover, IL-31 alone was sufficient to promote IL1A 
mRNA expression and, in contrast to SDS alone, able to trigger IL-1α release into the cell 
culture medium (Figure 6 D). Together these findings demonstrate, that IL-31 alters the 
skin barrier and promotes the uptake of allergens and pathogens in the skin. Moreover IL-
31 treatment induces IL1A gene expression and IL-1α release from an organotypic skin 
model. 
 
IL-31 PROMOTES TRANSEPIDERMAL WATER LOSS IN MOUSE MODEL 
To further determine the impact of IL-31 on skin differentiation in vivo, an epidermal 
mouse model based on a cell-sorted skin equivalent (CsSE) was refined (Wang et al., 2000; 
Skazik et al., 2014). Plastic chambers were transplanted on the back of SCID mice. Two 
days before transplanting the chamber, drinking water was supplemented with doxycycline 
to induce the IL-31 receptor expression in keratinocytes, which would be seeded later into 
the plastic chambers (Figure 7 A). One day after transplanting the chambers, HaCaT 
keratinocytes either expressing the IL-31 receptor (HaCaT-IL31RA) or not (HaCaT) were 
seeded together with human dermal fibroblasts (HDF) into these chambers. In Figure 7 B 
macroscopic pictures of CsSE on the back of a SCID mouse are shown. The mice were 
injected subcutaneously below the chambers with IL-31 daily till the end of the 
experiment, starting four days after seeding the cell slurry (Figure 7 A). At day six the 
chambers were removed and one-day later trans-epidermal water loss (TEWL) was 
measured in the different models. Measurement of TEWL is a non-invasive method for 
determining the barrier function of skin (Gioia and Celleno, 2002). Temperature and 
relative humidity were measured at two different heights above the skin in a hollow 
cylinder and by this TEWL is indirectly calculated. If the skin barrier is somehow damaged 
an increase of TEWL can be observed. HaCaT-IL31RA cells exhibited a profound defect 
in epidermal development with a reduction in filaggrin expression as observed in 
immunofluorescence imaging. It also showed a reduced lipid barrier formation visualized 
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by reduced nile red staining (Figure 7 C), resulting in disturbed barrier formation as 
shown by significant increased TEWL (Figure 7 D). 
 
 
Figure 7: IL-31 promotes transepidermal water loss. 
A. Treatment Procedure for generation of Cell-sorted Skin Equivalent (CsSE). Mice were fed with doxycycline and 
subcutaneously treated with 20 µg rhIL-31 at day 4 to 7. HaCaT or HaCaT-IL31RA cells were seeded together with human 
dermal fibroblast at day 0. B. Macroscopic pictures of a 6-day-old CsSE. C. Histological sections of CsSE were stained with 
HE, for filaggrin (green), the DNA with DAPI (blue), and lipids with nile red. Scale bar HE 200 µm, scale bar immuno 
fluorescence 100 µm. D. Transepidermal water loss (TEWL) was measured on 7 day old CsSEs, with a Tewameter, mean 
values ± SD, n = 3. P-values were calculated using Student’s t-test (* p<0.05; ** p<0.01; *** p<0.001). 
The data is part of Hänel et al., manuscript submitted. Animal experiments were performed in collaboration with and by 
Philipp M. Amann and Jens M. Baron (Department of Dermatology and Allergology, University Hospital Aachen). 
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IL-31 STIMULATES THE IL-1 NETWORK 
In the above-described experiments it was seen that IL-31 alone stimulates IL1A gene 
expression in differentiated organotypic skin models (Figure 6). To assess if the IL1 gene 
is a downstream target of IL-31 treatment in keratinocytes, qRT-PCR was used to analyze 
the expression of the IL1 gene family. IL-31 stimulated in a time-dependent manner the 
expression of IL1A and IL1B as well as the gene encoding the IL-1 receptor subunit IL1R2, 
in monolayer HaCaT-IL31RA cells (Figure 8 A). The IL-1 receptor subunit IL1R1 and the 
natural IL1 receptor antagonist IL1RN were not significantly regulated upon IL-31 
treatment (Figure 8 A). To further investigate if the IL-1 receptor subunits were also 
presented at the cell surface, FACS analysis of HaCaT-IL31RA monolayer cells was 
performed. This analysis revealed an increase of IL-1R2 at the cell surface upon 72 h IL-31 
treatment (Figure 8 B). It was of particular interest to determine whether the amount of 
intracellular IL-1α and IL-1β is affected by IL-31 stimulation and IL-1α and IL-1β is also 
released into the culture medium. To address this question, ELISA technique was used to 
monitor the intra- and extracellular amount of IL-1α and IL-1β upon IL-31 stimulation in 
HaCaT-IL31RA monolayer cells. An increase of both IL-1α and IL-1β concentration 
within the cells could be observed, whereas only the IL-1α concentration raised in the cell 
culture medium and no additional release of IL-1β was seen (Figure 8 C). 
 
This observation was further investigated in a slightly different experimental ELISA 
setting. The proinflammatory cytokine IL-1β is produced as an inactive precursor pro-IL-
1β in the cytosol after different stimuli. The inactive precursor is cleaved by caspase-1, 
which can be activated by cytosolic multi-protein-complexes called 'inflammasomes' 
(Franchi et al., 2012). Nigericin, a microbial toxin derived from Streptomyces 
hygroscopicus, was used to activate the NALP3 inflammasome. Upon treatment with 
either nigericin or IL-31, no additional release of IL-1β was seen but when HaCaT-
IL31RA monolayer cells were prestimulated with IL-31 and later challenged with 
nigericin, an increase of both IL-1α and IL-1β in the cell culture medium was observed 
(Figure 8 D). As mentioned before, there are large differences in the physiology and 
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reactions to substances and cytokines between keratinocyte monolayer cultures and 
organotypic skin models. This issue was addressed by determining the reactions regarding 
the IL-1 network also in 3D organotypic skin models. By immuno-histological staining an 
increase of IL-1α expression could be detected within a HaCaT-IL31RA organotypic skin 
model (Figure 8 E). Furthermore also the release of IL-1α from these models could be 
detected using ELISA technique (Figure 8 F). However release of IL-1β was not seen (data 
not shown), which was consistent with the findings in HaCaT-IL31RA monolayer cells 
(Figure 8 C).  
 
Two studies from 2011 showed that i) IL31 mRNA levels in skin lesions of AD patients 
correlate with their IL-31 serum levels (Kim et al., 2011) and ii) serum levels obtained 
from children during AD, during a flare, but also when quiescence, are significantly higher 
than those in healthy controls (Ezzat et al., 2011). Considering these studies, blood sera of 
26 AD patients were analyzed with ELISA technique to determine the concentration of IL-
31 and IL-1α. First the IL-31 levels were detected and sera were correspondingly grouped 
in a high level (above 4.1 ng/ml) and a low level (below 4.1 ng/ml) cohort. The 
measurement of IL-1α revealed that high IL-31 levels correlated with higher IL-1α levels 
(Figure 8 G). 
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Figure 8: IL-31 stimulates the IL-1 signaling network.  
A. qRT-PCR analysis of the indicated genes in monolayer HaCaT-IL31RA cells stimulated with 100 ng/ml rhIL-31 for the 
indicated times, mean values ± SD, n = 3. B. FACS analysis of IL-1R1 and IL-1R2 expression on monolayer HaCaT-IL31RA 
cells in response to 100ng/ml rhIL-31 (72 h), one representative experiment shown. C. IL-1α and IL-1β proteins were 
analyzed by ELISA from cell lysates and supernatants of monolayer HaCaT-IL31RA cells treated with 100 ng/ml rhIL-31, 
mean values SD, ± n = 3. D. Same setting as in C but cells were challenged with 20µM for 24 h of nigericin after 24 rhIL-31 
treatment, proteins were measured in the supernatant. mean values SD, ± n = 3. E. Histological sections of a 10-day-old 
HaCaT-IL31RA 3D organotypic skin model treated every second day with 100 ng/ml rhIL-31. The model was stained for IL-
1α (green) and for DNA (blue). Scale bar 200 µm. F. IL-1α was measured by ELISA in the supernatant of 3D organotypic 
skin models as in E, mean values ± SD, n = 3. G. IL-1α levels in 26 human sera were compared, 14 sera with an IL-31 
concentration below and 12 sera with an IL-31 concentration above 4.1 ng/ml. IL-1α and IL-31 levels were measured by 
ELISA. H. Monolayer HaCaT-IL31RA cells were treated with 100 ng/ml rhIL-31 for 4h. In addition, the indicated kinase 
inhibitors (JAK inhibitor I [100 nM]; c-Jun N-terminal kinase inhibitor II [20 µM]; SB202190, selective for p38 MAP kinases 
[20 µM]; U0126, selective for extracellular signal-regulated kinases [20 µM]; Wortmannin, selective for PI3K kinases [500 
nM]) were added 1 h prior to stimulation with rhIL-31. The expression of the indicated genes was analyzed using qRT-PCR 
and normalized to the rhIL-31 / DMSO control, mean values ± SD, n = 3. P-values were calculated using Student’s t-test (* 
p<0.05; ** p<0.01; *** p<0.001). 
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In addition, our research group has shown before that IL-31 induces the expression of 
IL20 and IL24 genes in HaCaT-IL31RA keratinocytes and that IL-20 and IL-24 may 
contribute to the IL-31 phenotype (Cornelissen et al., 2012b). To analyze if the induction 
of the genes encoding IL1A and IL1B was regulated similarly to the IL20 and IL24 
expression, monolayer HaCaT-IL31RA cells were treated with specific inhibitors for 
different signaling pathways downstream of the IL-31 receptor complex. Inhibitors 
targeting PI3K kinases, p38 and extracellular signal-regulated kinases (ERK) interfered 
with the induction of IL1A and IL1B by IL-31 (Figure 8 H; IL1B not shown but similar to 
IL1A data). However, a pan JAK inhibitor against JAK 1, JAK 2, JAK 3 and Tyk 2 used at 
a concentration more than 6-fold higher than the highest IC 50, did not inhibit the 
expression of both IL1A and IL1B in HaCaT-IL31RA cells (Figure 8 H). In contrast to 
these findings the induction of the expression of IL20 and IL24 was dependent on the JAK 
kinase, p38 and ERK pathways (Figure 8 H and (Cornelissen et al., 2012b)). In conclusion 
IL-31 induced the IL1A and IL1B expression via the PI3K, p38 and ERK pathways and 
induces the release of IL-1α. The release of IL-1β could only be detected after additional 
nigericin stimulation. Moreover high IL-31 serum levels correlated with higher IL-1α 
levels in AD patients. 
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IL-1 NETWORK IS NOT AFFECTED BY IL-20 AND IL-24 
As it was identified before that IL-31 affects the IL-1 signaling pathway, it should 
subsequently be tested, if this effect is direct or indirect, i.e. whether or not the genes of the 
IL-1 signaling network are directly controlled by IL-31 activated signaling pathways. IL-
31 effect. As already mentioned, IL-31 induces the gene expression of IL20 and IL24 
immediately after treatment (Cornelissen et al., 2012b). Furthermore IL-20 and IL-24 were 
shown to mediate parts of the IL-31 effect in organotypic skin modes (Cornelissen et al., 
2012b). Partially the same signaling pathways such as p38 and ERK were necessary to 
induce either IL1A or IL20 and IL24 gene expression (Figure 8 H and Cornelissen et al., 
2012b). Therefore it should be tested in the following experiments if IL1A or IL1B gene 
expression was triggered by IL-20 or IL-24. For this purpose 3D organotypic HaCaT-
IL31RA models were used and treated with IL-20, IL-24 or with both. Gene expression 
was analyzed after seven days of treatment using qRT-PCR. Neither IL-20 nor IL-24 nor a 
combination of both induced IL1A and IL1B gene expression (Figure 9). Interestingly the 
gene expression of both IL1 genes was slightly reduced upon treatment. 
 
 
Figure 9: IL-20 and IL-24 do not induce IL-1 gene expression.  
qRT-PCR analysis of the indicated genes in 10-day-old HaCaT-IL31RA organotypic skin models stimulated with 20 ng/ml of 
rhIL-20 or rhIL-24, mean values ± SD, n = 3. 
P-values were calculated using Student’s t-test (* p<0.05; ** p<0.01; *** p<0.001). 
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ROLE OF IL-1α IN IL-31 SIGNALING 
IL-1α AFFECTS THE SKIN BARRIER 
It has been shown by various research groups that IL-1α can influence the formation of the 
skin barrier (Wood et al., 1992; Barland et al., 2004; O'Shaughnessy et al., 2010). To 
investigate in which way IL-1α affects the expression of the essential skin barrier protein 
filaggrin, 10-day-old HaCaT-IL31RA and 5-day-old primary organotypic skin models with 
NHEK cells were used. After lifting the models to the air liquid interphase they were 
treated every second day with IL-31 or IL-1α. It could be observed that IL-1α inhibited 
FLG mRNA expression to a comparable extent as IL-31 (Figure 10 A). Moreover in 
monolayer cell culture experiments with HaCaT-IL31RA cells treated up to 72 h with IL-
1α, gene expression of desmosomal proteins and filaggrin processing enzymes was 
analyzed with qRT-PCR (Figure 5 C). IL-1α also altered the expression of desmosomal 
proteins, as shown before for IL-31 (Figure 5 C). In HaCaT-IL31RA cells treated with IL-
1α for up to 72 h the genes encoding desmoglein 1 and 4 (DSG1 and 4) but also 
desmocollin 1 and 2 (DSC1 and 2) and the genes encoding caspase-14 (CASP14) and 
kalikrein-like peptidase 7 (KLK7) were down regulated (Figure 10 B).  
 
 
Figure 10: IL-1α deregulates the expression of genes associated with the mechanical skin barrier. 
A. NHEK 3D organotypic skin model (one representative experiment) and HaCaT-IL31RA 3D organotypic skin model were 
stimulated with 100 ng/ml rhIL-31 and 10 ng/ml rhIL-1α, FLG expression measured by qRT-PCR mean values ± SD, n = 3. 
B. qRT-PCR analysis of the indicated genes in HaCaT-IL31RA monolayer cells stimulated with 10 ng/ml rhIL-1α, mean 
values ± SD, n = 3. P-values were calculated using Student’s t-test (* p<0.05; ** p<0.01; *** p<0.001). 
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These findings demonstrate that in our cell culture models IL-1α regulates the 
expression of filaggrin and desmosomal proteins in a comparable way to IL-31 (Figure 5 C 
and Figure 10 B). All genes analyzed with qRT-PCR after treating the cells either with IL-
31 or IL-1α were regulated in the same direction except for DSC2. DSC2 was up regulated 
upon IL-31 treatment (Figure 5 C) but repressed upon IL-1α treatment in monolayer cell 
culture experiments (Figure 10 B). Genes associated with skin differentiation i.e. FLG 
(Figure 10) and genes associated with the skin barrier i.e. DSG1, DSG4, DSC1, CASP14 
and KLK7 (Figure 5 and Figure 10) were regulated the same way upon either IL-31 or IL-
1α treatment. Moreover IL-31 induces directly or indirectly the IL-1 network with 
promoting the release of IL-1α into the extracellular space (Figure 8). These facts raised 
the question, if the effects regarding the skin barrier, which could be observed in 
organotypic models treated with IL-31, were indeed mediated via the IL-1 network. To 
evaluate the downstream effect of IL-1α after IL-31 treatment, the IL-1 receptor antagonist 
anakinra, which inhibits the binding of IL-1 to IL-1R1 was used (Dinarello et al., 2012). 
Anakinra (brand name Kineret®) is a potent IL-1 signaling inhibitor effectively used in 
patients suffering from rheumatoid arthritis (RA) and neonatal-onset multisystem 
inflammatory disease (NOMID) (Jesus and Goldbach-Mansky, 2014). Primary organotypic 
skin models with NHEK cells were cultivated for two day to examine mRNA expression 
and for five days to analyze protein expression. These models were either treated with IL-
31 or IL-1α every second day. Moreover anakinra was added to block the IL-1α signaling 
one-day prior to the cytokine treatment. Both IL-31 and IL-1α were able to suppress 
filaggrin gene and protein expression to a comparable extent (Figure 11 A and B). These 
downregulating effects of both IL-31 and IL-1α on filaggrin gene and protein expression 
were reverted by anakinra. This is indicated by the decreased green staining for filaggrin in 
the IL-31 and IL-1α treated samples and an increased staining intensity in the anakinra 
pretreated models (Figure 11 B). This implies that IL-1α may be at least partially 
necessary for the response to IL-31 (Figure 11 A and B). Anakinra alone had even a 
slightly increasing effect on filaggrin expression (Figure 11 B). 
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Figure 11: Role of IL-1α in IL-31 signaling. 
A. FLG expression in NHEK 3D organotypic skin model treated with 10 ng/ml rhIL-1α, 100 ng/ml rhIL-31 and one day before 
with 3 µg/ml anakinra (Ana) was analyzed by qRT-PCR, mean values ± SD, n = 3. B. NHEK 3D organotypic skin models 
were treated with cytokines and anakinra as described in A. Histological sections were stained with HE, for filaggrin (green) 
andthe DNA was stained with DAPI (blue). Scale bar HE 200 µm, scale bar immunofluorescence 100 µm. C. The indicated 
signaling molecules were analyzed by Western blot technique. HaCaT-IL31RA monolayer cells were pretreated with 3 µg/ml 
anakinra (Ana) one day before and then stimulated with 10 ng/ml rhIL-1α, 100 ng/ml rhIL-31 for the indicated time periods. 
Cells were pretreated with 3 µg/ml anakinra for 30 min as indicated. P-values were calculated using Student’s t-test (* 
p<0.05; ** p<0.01; *** p<0.001). 
As another step to investigate if the observed IL-31 effects in 3D models are a result of the 
IL-1 network, the activation of signaling kinases downstream of IL-1α were analyzed. The 
phosphorylation status of STAT3, p38 and p65, known downstream effectors of the IL-31 
and IL-1 signaling, were analyzed in HaCaT-IL31RA monolayer cells (Cornelissen et al., 
2012a; Barksby et al., 2007). Moreover degradation of the inhibitor protein I kappa B 
alpha (IκBα) was analyzed (Barksby et al., 2007). Cells were pretreated for 30 minutes 
with anakinra and the cytokines were added for the indicated time (Figure 11 C). Presence 
of IL-31 but not IL-1α promoted the phosphorylation of STAT3 and this effect was not 
inhibited by anakinra pretreatment. However, the phosphorylation of p65 and the 
degradation of IκBα was influenced by the presence of IL-1α but not IL-31 and this effect 
was blocked by anakinra pretreatment. On the other hand, addition of anakinra efficiently 
prevented the phosphorylation of the MAP-Kinase p38, which was enhanced in the 
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presence of each, IL-31 or IL-1α. Summarizing, anakinra pretreatment blocks IL-31 and 
IL-1α mediated filaggrin reduction. Moreover both cytokines IL-31 and IL-1α induce p38 
phosphorylation but only IL-1α induces p65 phosphorylation and the degradation of IκBα. 
IL-31 induces STAT3 phosphorylation. 
 
REGULATION OF ANTIMICROBIAL PEPTIDES BY IL-31 IS 
DEPENDENT ON IL-1α INDUCTION 
IL-1α REGULATES THE EXPRESSION OF AMPS 
In addition to effects on various genes encoding proteins associated with barrier function, 
literature data supports that several genes encoding antimicrobial peptides (AMPs) are 
induced in response to IL-1α including genes encoding S100 Ca2+-binding proteins, human 
beta defensin 2 (hBD2/DEFB4A) and human beta defensin 3 (hBD3/DEFB103A) (Yano et 
al., 2008; Bando et al., 2007). To check if the genes encoding for S100A7, S100A8, 
S100A9, S100A12, DEFB103A and DEFB4A respond to IL-1α in HaCaT-IL31RA 
monolayer cultures, their expression was analyzed by qRT-PCR. The expression of 
DEFB4A was significantly increased within 24 h of IL-1α treatment (Figure 12). However 
DEFB103A gene expression was not significantly induced upon IL-1α treatment. The 
analyzed S100 genes, S100A7, S100A8, S100A9 and S100A12 were induced upon IL-1α 
treatment. In contrast to S100A7 and S100A12, gene expression of S100A8 and S100A9 
was increased within the first 48 h but the induction was reduced to a lower level after 72 h 
(Figure 12). 
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Figure 12: IL-1α regulates the expression of antimicrobial peptides. 
HaCaT-IL31RA cells were stimulated with 10 ng/ml rhIL-1α for the indicated time periods and gene expression was 
analyzed with qRT-PCR, mean values ± SD, n = 3. P-values were calculated using Student’s t-test (* p<0.05; ** p<0.01; *** 
p<0.001). 
In summary IL-1α inhibited the FLG expression in HaCaT and NHEK organotypic skin 
models as well as the expression of desmosomal proteins (Figure 10 and Figure 12). 
Furthermore it also induced the expression of AMPs (Figure 12), which are a known 
defense mechanism of the skin (Schröder and Harder, 2006). 
 
IL-31 INFLUENCES THE EXPRESSION OF AMPS 
As seen before, IL-1α mediates downstream effects of IL-31 on the filaggrin protein and 
gene expression level (Figure 11). Furthermore it was shown that IL-1α induced the 
expression of AMPs in HaCaT-IL31RA cells. These findings lead to the question whether 
IL-31 can induce the expression of antimicrobial peptide genes in a similar manner as IL-
1α. The gene expression of S100A7, S100A8, S100A9, S100A12, DEFB103A and DEFB4A 
was analyzed in HaCaT-IL31RA monolayer cultures stimulated with IL-31 for up to 72 h 
using qRT-PCR (Figure 13 A). The expression of all genes was significantly increased 
upon IL-31 stimulation. The AMP encoding genes were also induced by IL-1α in HaCaT-
IL31RA cells, as indicated previously, albeit the effect was less strong in comparison to the 
response to IL-31 (Figure 12). Moreover when organotypic HaCaT-IL31RA models were 
challenged with IL-31, the concentration of human beta defensin proteins in the cell culture 
medium was increased (Figure 13 B). Additionally staining intensity of S100A7 and 
S100A9 proteins was enhanced in 10-day-old 3D organotypic models after IL-31 
stimulation (Figure 13 C). 
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Figure 13: IL-31 regulates the expression of antimicrobial peptides. 
A. HaCaT-IL31RA cells were stimulated with 100 ng/ml rhIL-31 for the indicated time periods and gene expression was 
analyzed by qRT-PCR, mean values ± SD, n = 3 B. The indicated proteins were measured by ELISA in the supernatants of 
10-day-old HaCaT-IL31RA 3D organotypic skin models stimulated every second day with 100 ng/ml rhIL-31, mean values ± 
SD n = 3. C. Histological sections of 10-day-old HaCaT-IL31RA 3D organotypic skin models stimulated every second day 
with 100 ng/ml rhIL-31were stained with HE, for the indicated proteins (green), and the DNA was stained with DAPI (blue). 
Scale bar 100 µm. P-values were calculated using Student’s t-test (* p<0.05; ** p<0.01; *** p<0.001). 
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To further analyze the IL-31 mediated AMP gene expression, pulse experiments were 
performed. Our research group had shown that only a relative short IL-31 pulse was 
sufficient to de-regulate the differentiation process in keratinocytes, with filaggrin as a 
sensitive marker. A reduction of FLG expression in 3D organotypic skin models measured 
after 7 days could be observed after an IL-31 pulse of 2 h at the first day, while other genes 
responded less sensitive (Cornelissen et al., 2012b). Inspired by these effects on 
differentiation, the pulse experiment was used to analyze AMP gene expression. 7-day-old 
organotypic HaCaT-IL31RA models were treated at the first day of differentiation with IL-
31 for 2, 4, 6, 8 h or were treated permanently for the 7 days (Figure 14). Afterwards the 
IL-31 pulse medium was changed and the models were cultivated in the absence of IL-31. 
DEFB103A was already induced 20-fold after a 2 h IL-31 stimulation whereas induction of 
DEFB4A and S100A7, S100A8, S100A9 and S100A12 required a permanent IL-31 
presence. 
 
 
Figure 14: Permanent IL-31 treatment induces AMP expression. 
qRT-PCR analysis of the indicated genes in HaCaT-IL31RA organotypic 3D models stimulated with 100 ng/ml rhIL-31 for 
the indicated times at day 0 or permanent every second day. Skin equivalents were harvested after 7 days, mean values ± 
SD, n = 3. P-values were calculated using Student’s t-test (* p<0.05; ** p<0.01; *** p<0.001). 
Overall the analyzed data indicated that both cytokines IL-1α and IL-31 promote the 
expression of antimicrobial peptides in HaCaT-IL31RA cells, irrespective of monolayer or 
3D cultured. Furthermore the release of certain AMPs, i.e. hBD-2 hBD-3, S100A9 and 
S100A12, into the cell culture medium upon IL-31 treatment could be shown. 
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REGULATION OF ANTIMICROBIAL PEPTIDES BY IL-31 IS 
DEPENDENT ON IL-1α INDUCTION 
In former experiments it was seen that the presence of either IL-1 (Figure 12) or IL-31 
(Figure 13) triggered the expression of AMPs in keratinocytes. As a next step it should be 
tested, if IL-1 is required for the IL-31 effect on AMPs by the use of the IL-1 receptor 
antagonist anakinra. Therefore HaCaT-IL31RA monolayer cells were stimulated for 72 h 
with IL-31, IL-1α and anakinra, or a given combination. All genes analyzed were not at all 
or to a lesser extent induced by IL-31 when the IL-1 signaling was blocked by anakinra. 
This also applied to the induction with IL-1α (Figure 15). 
 
 
Figure 15:Regulation of antimicrobial peptides by IL-31 is dependent on IL-1α induction. 
The indicated genes were analyzed by qRT-PCR. HaCaT-IL31RA monolayer cells were treated for 72 hours with either 
10 ng/ml rhIL-1α, 100 ng/ml rhIL-31 and 3 µg/ml anakinra (Ana), mean values ± SD, n = 3. P-values were calculated using 
Student’s t-test (* p<0.05; ** p<0.01; *** p<0.001). 
In summary all these results show that the presence of IL-1 is necessary for the induction 
of AMPs by IL-31, as seen before for the regulation of differentiation markers i.e. FLG and 
for the regulation of different barrier proteins. 
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ROLE OF LOW IL-31 DOSES IN HUMAN SKIN BARRIER 
FORMATION 
IL-31 prevents the formation of the mechanical barrier but stimulates the antimicrobial 
barrier. To evaluate whether these two effects can be separated and furthermore to identify 
a potential role of IL-31 in healthy human skin, IL-31 was titrated in HaCaT-IL31RA 3D 
organotypic skin models and skin differentiation was analyzed after ten days. As shown 
before, 100 ng/ml of IL-31 were sufficient to prevent filaggrin expression and terminal 
differentiation (Figure 5, Figure 7 and Figure 11 and (Cornelissen et al., 2012b)). Even a 
dose of 10 ng/ml of IL-31 could prevent filaggrin expression in organotypic HaCaT-
IL31RA 3D models (Figure 16 A). Lower doses had no significant effects on the gene 
expression of the differentiation marker FLG and INV and on the expression of 
desmosomal proteins (Figure 16 B), and were also insufficient to prevent filaggrin protein 
expression (Figure 16 A).  
 
However at a concentration of 1 ng/ml IL-31 enhanced expression of IL1A and IL1B and of 
the genes encoding several antimicrobial peptides (S100A8, S100A9, S100A12, DEFB103A 
and DEFB4A) was observed in HaCaT-IL31RA monolayer cells after 72 h (Figure 16 C). 
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Figure 16: Role of low IL-31 doses in human skin barrier formation. 
A. HaCaT-IL31RA 3D organotypic skin models were stimulated with rhIL-31 in the indicated concentration every second day 
for 10 days and histological sections were stained with HE or for filaggrin (green) and DNA with DAPI (blue). Scale bar HE 
200 µm, scale bar IF 100 µm. B. qRT-PCR analysis of the indicated genes in 10-day-old HaCaT-IL31RA 3D organotypic 
models stimulated as in A, mean values ± SD, n = 3. C. qRT-PCR analysis of the indicated genes in HaCaT-IL31RA cells 
treated for 72 h with the indicated concentration of rhIL-31, mean values ± SD, n = 3. P-values were calculated using 
Student’s t-test (* p<0.05; ** p<0.01; *** p<0.001). 
Taken together these findings demonstrate that low doses of IL-31 enhance the expression 
of genes encoding AMPs (Figure 13 and Figure 16), whereas higher doses have a profound 
effect on the mechanical barrier (Figure 6 and Figure 7). 
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IL-31 PROMOTES THE EXPRESSION AND RELEASE OF TSLP 
Various studies either in mice or in dogs have shown that IL-31 has an important role in 
inducing itch (Takaoka et al., 2006; Dillon et al., 2004; Gonzales et al., 2013; Arai et al., 
2013). In further support of this hypothesis IL-31 expression is increased in the lesional 
skin of AD patients and the IL-31 receptors are localized in dorsal root ganglia. Recent 
studies have shown that repeated administration of IL-31 in mice also increased the 
expression of IL-31 receptors in dorsal root ganglia (Arai et al., 2014). 
 
A recent clinical study addressed the role of IL-31 in human skin in vivo. Ten patients with 
AD and ten healthy volunteers were challenged with IL-31 and NaCl (negative control) by 
skin prick testing (Hawro et al., 2014). They concluded that IL-31 does not induce 
immediate itch responses in humans. Furthermore the late onset of IL-31-induced itch 
supports the notion that IL-31 exerts its pruritic effect indirectly via keratinocytes and 
secondary mediators, rather than through its receptors on cutaneous nerves (Hawro et al., 
2014). Sooner afterwards it was demonstrated that IL-31 treated epidermal models were a 
source of TSLP (Danso et al., 2014). Moreover two papers revealed that the receptor 
complexes IL-31 and TSLP mediate itch via the same subset of neurons. TSLP acts 
directly on a subset of TRPA1 positive sensory neurons to trigger itch behavior (Wilson et 
al., 2013b). IL-31 mediated itch was significantly reduced in TRPA1 and TRPV1-deficient 
mice (Cevikbas et al., 2013). Altogether these findings let to the idea that IL-31 treatment 
on keratinocytes may promote the secretion of TSLP and by this mediate itch behavior. 
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Figure 17: IL-31 promotes the expression and release of TSLP. 
A. TSLP gene expression was analyzed in monolayer HaCaT-IL31RA cells upon treatment with 100 ng/ml rhIL-31 using 
qRT-PCR. B. TSLP in the supernatant of a 10-day-old HaCaT-IL31RA 3D model treated every second day with 100 ng/ml 
rhIL-31, mean values ± SD, n = 3. C. TSLP in the supernatant of a 5-day-old NHEK 3D organotypic skin model treated with 
100 ng/ml rhIL-31 for the indicated time periods, mean values ± SD, n = 3. D. TSLP gene expression was analyzed in 
HaCaT-IL31RA skin models upon treatment with 10 ng/ml rhIL-1α or rhIL-1β using qRT-PCR, mean values ± SD, n = 3. P-
values were calculated using Student’s t-test (* p<0.05; ** p<0.01; *** p<0.001). 
To test if IL-31 affects TSLP gene expression and TSLP release from keratinocytes, qRT-
PCR were performed on samples from monolayer HaCaT-IL31RA cells treated with IL-31 
for up to 72 h. A significant increase expression of the TSLP gene was observed (Figure 
17 A). To test if TSLP is also released from HaCaT-IL31RA 3D organotypic skin models 
into the cell culture medium, ELISA was performed after ten days of stimulation with IL-
31. A significant increase of TSLP concentration in the cell culture medium was measured 
(Figure 17 B). To identify if TSLP could be a possible secondary mediator upon IL-31 
treatment. A five-day-old organotypic skin equivalent was apically challenged with IL-31 
and a sample of the surrounding cell culture medium was taken every 30 min. Release of 
TSLP into the medium was measured by ELISA. TSLP was measured first 30 min after IL-
31 application, TSLP concentration peaked at 1.5 h (20 pg/ml) and after 2.5 h no TSLP 
could be detected in the medium anymore (Figure 17 C). As shown before, several genes, 
which were induced by IL-31, were indirect IL-31 target genes and were induced by either 
IL-1α or IL-1β. As a consequence HaCaT-IL31RA monolayer cells were treated either 
with IL-1α or with IL-1β for up to 72 h and TSLP gene expression was analyzed. No 
significant change in TSLP gene expression could be observed by treatments with both 
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cytokines (Figure 17 D). In summary IL-31 promotes TSLP gene expression and release 
from HaCaT-IL31RA keratinocytes an effect that appeared independent of IL-1α or IL-1β. 
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3 DISCUSSION 
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ROLE OF IL-31 IN ATOPIC DERMATITIS 
AD is a common chronic inflammatory disease characterized by a defect in keratinocyte 
differentiation and skin barrier formation (Leung and Bieber, 2003). Consequences of the 
impaired skin barrier are the increased percutaneous penetration of allergens and 
pathogens, thereby promoting inflammation that can be further aggravated by secondary 
infections. Furthermore the impaired skin barrier is characterized by an increased TEWL. 
Alterations in genes encoding key structural components for proper keratinocyte 
differentiation and skin barrier formation are associated with barrier dysfunction. A 
seminal finding was the identification of FLG mutations in patients with ichthyosis 
vulgaris and AD (Smith et al., 2006; Palmer et al., 2006; Sandilands et al., 2007; Brown 
and McLean, 2012). Also cytokines are deregulated in AD patients and were postulated to 
participate in disease progression (Leung and Bieber, 2003; Hanel et al., 2013). One of 
these deregulated cytokines is IL-31. Serum IL-31 expression is increased and correlates 
with disease severity in these patients (Kim et al., 2011; Neis et al., 2006; Raap et al., 
2008; Nobbe et al., 2012). Furthermore IL31 mRNA levels of lesional AD skin are 
elevated compared to non-lesional and healthy skin (Sonkoly et al., 2006). IL31 transcripts 
could be further induced after topical exposure of the non-lesional skin of AD patients to 
either dust mite allergens (from D. farinae and D. pteronyssimus) or staphylococcal super 
antigens (SEB and TSST-1) (Sonkoly et al., 2006). Source of IL-31 production in the skin 
are either resident or infiltrating immune cells (Cornelissen et al., 2012a). One major 
population that produce IL-31 are activated T-cells. Upon treatment with various 
inflammatory stimuli such as UV radiation, allergens, pathogens and histamines, T-cells 
promote IL31 gene expression and the release of IL-31 (Bilsborough et al., 2006; 
Cornelissen et al., 2011; Dillon et al., 2004; Gutzmer et al., 2009; Sonkoly et al., 2006). 
Recently it was shown that IL-4, a prominent cytokine in AD, induces IL-31 expression in 
TH1 cells (Stott et al., 2013) and downregulates FLG expression (Howell et al., 2009). 
This subset of T-cells was also shown to have upregulated IL31 mRNA expression upon 
activation with either anit-CD3 or anti-CD28 (Zhang et al., 2008). Moreover circulating T-
cells positive for the skin-homing cutaneous lymphocyte antigen (CLA) produce IL-31. 
Furthermore, cells isolated from patients with AD produce higher levels of IL-31 
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compared to either psoriasis patients or healthy individuals (Bilsborough et al., 2006). 
By recognizing skin related allergens these CLA positive cells accumulate in acute lesions 
of AD and release higher amounts of IL-4 and IL-13 (Akdis et al., 1997). Furthermore 
mast cells induce IL31 mRNA expression when treated with the antimicrobial peptides, 
such as hBDs (hBD-1 to hBD-4) or LL-37, an effect that could be further enhanced by 
pretreating the cells with IgE (Niyonsaba et al., 2010). AD lesions providing an 
inflammatory environment, with elevated IgE levels. Only 10% of skin lesions are not 
colonized with S. aureus resulting in an increased amount of bacteria antigens and an 
increased expression of antimicrobial peptides. All these products promote the expression 
and release of IL-31 from various cell (Leung, 1997; Guttman-Yassky et al., 2011; Ott et 
al., 2009). Due to this IL-31 seems to have a major contribution to the pathomechanism of 
AD.  
 
IL-31 WEAKENS THE SKIN BARRIER 
Previously our research group demonstrated that IL-31 inhibits keratinocyte proliferation 
and differentiation without affecting apoptosis with FLG being a repressed target of IL-31 
signaling (Cornelissen et al., 2012b). However it remained open whether FLG is one of 
few genes that are deregulated in response to IL-31 or whether this cytokine has a broader 
effect on skin differentiation and barrier formation. Moreover it was unclear whether IL-31 
signaling was directly or indirectly responsible for affecting FLG expression. 
 
In this work it was observed that IL-31 interferes with the expression of many genes 
associated with skin barrier formation in 3D organotypic skin models of HaCaT-IL31RA 
cells, in contrast to monolayer cultures where only a few genes were deregulated 
(Cornelissen et al., 2012b). HaCaT-IL31RA cells were preferably used because primary 
NHEK cells often show donor dependent variability, which was noted before by studying 
the response to rhIL-31. HaCaT cells, as a donor independent cell system, are 
spontaneously immortalized primary keratinocytes that are able to differentiate in 
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organotypic skin models (Boukamp et al., 1988). HaCaT cells do not express the IL-
31RA but still express the OSM receptor, which is one of the subunits of the heterodimeric 
receptor complex. That is why a cell line was established in our group that expresses the 
IL-31RA under the control of doxycycline (Cornelissen et al., 2012b).  
 
Altogether Affymetrix exon array data identified approximately 570 genes that were 
altered more than two-fold in response to IL-31. Indeed many genes encoding proteins 
associated with corneodesmosomes, such as desmogleins or desmocolleins, with the 
formation of terminally differentiated corneocytes and with the production of natural 
moisturizing factors, including filaggrin and its processing enzymes caspase-14 and KLK7, 
were deregulated in response to IL-31 (Figure 5). The findings made by the Affymetrix 
arrays were only partially reproduced in the monolayer culture but completely consistent 
with findings in the organotypic skin models (Figure 5). This suggests that observations 
made in monolayer cultures have to be carefully interpreted. This may be related to the 
lack of appropriate cellular interactions. 3D organotypic skin cultures with fibroblasts 
serve as a more physiological model for epidermal development and homeostasis, in which 
a calcium gradient develops in the epidermal layer, which is comparable to normal skin. As 
a result a complete skin-like epidermal barrier is formed. Moreover fibroblasts provide 
physiologically relevant cytokines and growth factors that lack in monolayer cultures. In 
contrast monolayer cultures are a highly simplified and rather rudimental model and results 
generated in this model should be interpreted with caution and always compared with 
results from either organotypic or in vivo models or ideally should be confirmed in these 
settings.  
 
The observations made in monolayer and organotypic 3D skin models (Figure 5) implicate 
that IL-31 treatment does not only modulate keratinocyte differentiation and proliferation 
as shown before (Cornelissen et al., 2012b) but also affects the gene expression pattern of 
desmosomal and filaggrin processing enzymes such as CASP14 and KLK7 (Figure 5). 
Interestingly IL-31 did not affect the expression pattern of genes expressing tight junction 
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proteins (Figure 5). In contrast to this finding treatment of keratinocytes with high 
amounts of histamine results in a similar expression pattern of structural proteins, 
including filaggrin and keratin 10 (Gschwandtner et al., 2013; Cornelissen et al., 2012b), 
but it also affects the expression of tight junction proteins beyond the expression of 
desmosomal structures (Gschwandtner et al., 2013). Thus IL-31 showed a more selective 
effect in the experiments displayed in this work (Figure 5). This argues for different 
signaling pathways controlling different aspects of the differentiation process in 
keratinocytes. Consistent with these findings bronchial epithelia cells also show no 
alteration of the tight junctions determined by transepithelial electrical resistance when 
they were treated with IL-31 (Parker et al., 2012). 
 
The functional consequences of suppressed desmosomal gene expression were confirmed 
by assessing the integrity of the skin barrier in an organotypic skin model (Figure 6) and in 
a CsSE model (Figure 7). Within these models poor differentiation and reduced expression 
of late differentiation markers, e.g. filaggrin and lipids, could be observed (Figure 6 and 
Figure 7). Moreover an increased penetration of biotin from the dermal site, and the phl p1 
allergen from the apical site into 3D models was seen (Figure 6). Additionally high 
vulnerability to skin irritants and enhanced TEWL were measured (Figure 6 and Figure 7). 
All these observations point to a severe disturbance of the mechanical and functional 
properties of the skin barrier regarding formation of the cornified envelope. Additionally a 
defect in cellular adhesion could be implicated by the enhanced penetration of biotin from 
the dermal site (Figure 6). These findings are consistent with the change in desmosomal 
gene expression upon IL-31 treatment (Figure 5) and the reduced expression of 
keratinocyte differentiation markers such as filaggrin and keratin 10 as shown before 
(Cornelissen et al., 2012b). The impaired formation of the cornified envelope upon IL-31 
treatment may be a cooperative effect between the reduction of filaggrin, filaggrin 
processing enzymes, keratin 10, and desmosomal proteins. This idea is supported by the 
finding that filaggrin is essential for the formation of the stratum corneum and for skin 
barrier function (Mildner et al., 2010; Sandilands et al., 2009). The enhanced penetration of 
biotin also implies that IL-31 treated keratinocytes did not form a basal membrane 
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structure (Figure 6). These might also be explained by the disorganized β4-integrin, 
which in untreated organotypic models is located at the basal membrane and in IL-31 
treated models spreads through all epidermal layers (Cornelissen et al., 2012b). However 
disorganization of β4-integrin might not be the only cause but the disturbance of the basal 
membrane structure might be further mediated or supported by the reduced expression of 
desmosomal proteins (Figure 5). 
 
In summary different in vitro and in vivo approaches were used, namely monolayer cell 
culture experiments, organotypic 3D models, and a mouse model, to further define the role 
of IL-31 for the skin barrier integrity. Together these findings are consistent with the IL-
31-induced defect in skin differentiation observed previously (Cornelissen et al., 2012b) 
and suggest defects in the mechanical barrier due to reduced expression of structural 
proteins and corneodesmosomes. Furthermore IL-31 exhibits the potential to increase the 
irritating properties of different external stimuli as shown for SDS (Figure 6). These 
findings indicate that IL-31 may play an important role in altering the skin barrier. All 
these features shown here to be triggered by IL-31 treatment were also found in the skin of 
AD patients (Neis et al., 2006), strengthening the idea that elevated IL-31 concentrations in 
the skin of AD patients not only correlate with the disease sights and symptoms but IL-31 
also seems to be a driver of the pathogenic mechanism leading to the AD skin phenotype. 
 
Recently an ‘outside-inside,’ then back to ‘outside’ pathogenic mechanism in AD was 
postulated, expanding on the previous view that AD is largely a disease of immunologic 
etiology (Cornelissen et al., 2012b; Elias and Schmuth, 2009). The authors suggested that 
primary inherited barrier abnormalities in AD ultimately stimulate downstream paracrine 
mechanisms that could further compromise skin barrier function, driving an ‘outside-
inside-outside’ pathogenic loop in AD. This model suggests a cyclic interplay between 
inherited barrier abnormalities and exogenous and endogenous stressors with key functions 
of different secreted signaling molecules. More precisely, inherited barrier abnormalities 
allow enhanced uptake of allergens and antigens, which trigger increased IL-31 expression, 
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as well as other factors, in immune cells, including Th2 cells, and enhanced IL-31RA 
expression on keratinocytes (Cornelissen et al., 2012a). The elevated IL-31 expression can 
then result in a negative feedback loop in which the released IL-31 affects again the skin 
barrier. The findings made in this thesis endorse this model. 
 
IL-31 STIMULATES THE IL-1 NETWORK 
Of particular interest was the observation that not only expression of many genes encoding 
components of the IL-1 signaling network was affected by IL-31 but also an increased IL-
1α and IL-1β release was stimulated by IL-31 (Figure 8 A-C, E, F), supporting a concept in 
which IL-1 signaling is downstream of IL-31. Interestingly, a combination of IL-31 and the 
inflammasome activator nigericin resulted in a synergistic effect concerning IL-1α and IL-
1β release (Figure 8 D). Considering the increase of the intracellular concentrations of IL-
1α and IL-1β (Figure 8 C) the synergistic effect can be explained by the cleavage of pro-
IL-1β by caspase-1, which is activated upon inflammasome activation (Barksby et al., 
2007). The cleaved and activated IL-1β is then released from the cell either by small 
plasma membrane microvesicles (MacKenzie et al., 2001) or endocytotic vesicles (Andrei 
et al., 2004). This synergistic effect is in line with other observations in monocytes. In 
these cells a second stimulus is required to release active IL-1 cytokines. An initial 
stimulus, e.g. LPS, causes accumulation of pro-IL-1β in the cytosol and only a modest IL-
1β secretion (Dinarello, 1998). IL-1β release is then strongly induced by extracellular 
adenosine triphosphate (ATP) that activates procaspase-1 and subsequently pro-IL-1β 
(Ferrari et al., 2006). Together these results suggest that IL-1 signaling is an important 
mediator of the effects of IL-31 (Figure 11 and Figure 15). The importance of these 
findings is supported by published findings of known consequences of this network on skin 
diseases. The proinflammatory IL-1 signaling network is known to be an important 
mediator of innate immunity (Dinarello, 2009). Physiological levels of IL-1α enhance 
barrier formation and wound healing following mechanical injury (Barland et al., 2004; 
Jung et al., 2010), promote the synthesis of epidermal lipids and the formation of lamellar 
bodies, and induce the upregulation of genes and proteins associated with cell adhesion, 
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proliferation and epidermal differentiation in keratinocytes (Barland et al., 2004; Jung et 
al., 2010; Yano et al., 2008). In contrast, deregulation of the IL-1 signaling network has 
been associated with different skin diseases, including AD (Jensen, 2010). Thus over-
activation of the network, for example due to mutations in inflammasome components or 
as a result of IL-1RA deficiency, can lead to autoinflammatory diseases with severe skin 
involvement (Contassot et al., 2012; Schmitz et al., 2011). Indeed increased secretion of 
IL-1α has been observed in lesional skin of patients with psoriasis (Barksby et al., 2007). 
Exposure of keratinocytes to IL-1α provokes hyperkeratosis (O'Shaughnessy et al., 2010) 
and enhanced expression of IL-1α, e.g. by intradermal injection, promotes an inflammatory 
skin phenotype (Jung et al., 2011). Additionally, keratinocyte-specific overexpression of 
IL-1α leads to the development of spontaneous inflammatory skin lesions in mice (Groves 
et al., 1995). The findings of this work, e.g. the reduction in filaggrin expression on gene 
and protein level after IL-1α or IL-31 treatment (Figure 10 A and Figure 11 A and B), 
support the inhibitory character of IL-1α for keratinocyte differentiation with IL-31 
playing an important upstream role (Figure 8), suggesting that this cascade of cytokines 
controls skin differentiation. This is also supported by the observation that the effect of 
either IL-31 or IL-1α to repress filaggrin expression was abolished when the IL-1 signaling 
cascade was inhibited by anakinra (Figure 11 A and B). Moreover hyperkeratosis and other 
effects suggest that IL-31 controls through additional pathways other aspects that modify 
IL-1α signaling. The putatively involved signaling pathways and kinases will be discussed 
in more detail below.  
 
Furthermore by regulating the NF-κB signaling, IL-1α also regulates immune-reactive 
properties of IFN-γ (Hurgin et al., 2007), which is the mayor stimulus to induce the 
expression of the IL-31 receptor on keratinocytes (Heise et al., 2009). Moreover these 
signaling pathways offer entry sites for crosstalk with other signals that might influence 
differentiation. It is also of interest that FLG loss-of-function mutations are associated with 
enhanced IL-1α and IL-1β expression (Kezic et al., 2012). Besides the stimulation with IL-
31 keratinocytes produce IL-1α upon mechanical injury by UVB. Furthermore the 
proinflammatory cytokine TNF-α induces the expression of IL-1α (Kutsch et al., 1993) and 
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vice versa IL-1α induces TNF-α expression and release from endothelia cells (Imaizumi 
et al., 2000). Studies with knockout mice show that IL‐1α is important for T-cell priming 
during contact hypersensitivity and for the induction of high levels of serum IgE following 
immunization with ovalbumin and furthermore IL-1 induce the proliferation and survival 
of T-cells (Sims and Smith, 2010). To sum up IL-1α and IL-1β induce gene expression in 
different immune cell types, such as monocytes or macrophages, epithelial and endothelial 
cells, and chondrocytes or fibroblasts (Jeong et al., 2004; Wolter et al., 2008; Holzberg et 
al., 2003; Vincenti and Brinckerhoff, 2001; Allantaz et al., 2007). By elevating the levels 
of intracellular IL-1α and IL-1β without releasing IL-1β as seen in this work (Figure 8 A-
D), IL-31 primes the cells for a second stimulus leading to an aggravated immune reaction 
in the skin. Interestingly IL-1β is required for neutrophil recruitment and an effective 
innate immune response against cutaneous challenges with the pathogen S. aureus in an in 
vivo mouse model (Miller et al., 2007). Upon contact with staphylococcal exotoxin T-cell 
produce and release IL-31 (Sonkoly et al., 2006). Moreover IL-31 increases the 
intracellular levels of IL-1β in keratinocytes (Figure 8 C), which can be released upon an 
additional stimulus such as nigericin (Figure 8 D). This potential cascade indicates a role 
for IL-31 immune response against the pathogen S. aureus.  
 
However both cytokines, IL-1α and IL-1β, are required for full development of asthma. 
They promote eosinophil infiltration into the lung, goblet cell hyperplasia, adhesion 
molecule expression, production of IL-4, IL-5 and allergen-specific IgG and IgE 
antibodies, and airway hyper responsiveness (Sims and Smith, 2010). As mentioned in the 
introduction 80% of all children suffering from AD develop rhinitis or asthma during their 
lifetime (Eichenfield et al., 2003). The increased gene expression of IL1A and IL1B as well 
as the boosted release of IL-1α and the elevated intracellular amount of IL-1β upon IL-31 
treatment could promote the progression of the atopic march. 
 
As mentioned before, by elevating the levels of intracellular IL-1α and IL-1β, without 
releasing IL-1β, IL-31 primes the cells for a second stimulus leading to an aggravated 
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immune reaction in the skin, which would not appear if the IL-1 network would not be 
active. The patients' sera analysis has also shown that a correlation between IL-31 and IL-
1α is not only present in the in vitro models, but there is also a correlation between 
elevated IL-31 serum levels and increased IL-1α serum levels in patients. 
Due to the indirect modulation of the IFN-γ signaling as mentioned above, the elevated 
levels of IL-1α might have an effect on IL-31RA signaling, Moreover by inducing IL-1α 
gene expression and release IL-31 seems to induce a feed-forward loop which enhances 
signaling. By this IL-31 might be an important cytokine in an inflammatory environment 
as provided in acute AD lesions. It could be that elevated IL-31 levels over a longer time 
period lead to a formation of a chronic inflammatory environment and by this to disease 
progression.  
 
Having set these observations in a larger disease-related context, it is now interesting to 
evaluate the relationship between IL-31 and the IL-1 network more profoundly on a 
molecular level. Analysis of different IL-31 downstream signaling pathways showed that 
IL1A and IL20/IL24 expression was affected by different pathways, such as p38 MAP 
kinase and ERK pathway (Figure 8 H). Interestingly the IL-31 targets IL-20 and IL-24 in 
combination showed an effect on keratinocyte differentiation (Cornelissen et al., 2012b) 
but neither IL-20 nor IL-24 induced the expression of IL1A or IL1B. This implies that IL-
31 affects the skin barrier via a minimum of two different effector networks, which must 
be regulated by different signaling pathways downstream of the IL-31 receptor (Figure 
8 H). These networks were also compared in monolayer cell culture. Although it was 
discussed above that this experimental setting should be interpreted with caution, it can 
provide first indications of pathways for future studies. It could be observed that the 
addition of anakinra efficiently prevented the phosphorylation of the MAP kinase p38, 
which was enhanced in response to IL-31 or IL-1α. However, the phosphorylation of p65 
and the degradation of IκBα was influenced by the presence of IL-1α but not IL-31 and 
this effect was also blocked by anakinra. These differences in phosphorylation and 
degradation of downstream signaling molecules might be due to the fact that after IL-31 
stimulation IL-1α must be efficiently released from the cells before it can activate the 
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signaling pathway. Moreover the induced phosphorylation of p38 upon IL-31, which is 
inhibited by the addition of anakinra, again supports a possible downstream role of IL-1α 
in IL-31 signaling. 
 
Altogether IL-31 induces many of different cytokines such as IL-1α, IL-1β, IL-20 and IL-
24 when acting on keratinocytes. Through these targets IL-31 is able to influence a variety 
of different processes in the human skin and possibly in other organs when these mediators 
are released into the serum. 
 
REGULATION OF ANTIMICROBIAL PEPTIDES BY IL-31 IS 
DEPENDENT ON IL-1α INDUCTION 
IL-31 also modulated the expression of genes encoding different AMPs in monolayer cell 
cultures as well as in 3D skin models (Figure 13 and Figure 14). These effects were at least 
in part dependent on the activation of the IL-1 signaling network as they were inhibited by 
anakinra (Figure 15). These observations are in line with literature data as IL-1α has been 
known to regulate AMP expression in several cell types, including keratinocytes ((Figure 
12) (Bando et al., 2007; Jung et al., 2011; Hayashi et al., 2007; Krisanaprakornkit et al., 
2003; Liu et al., 2002; Moon et al., 2002)). Still it is striking that IL-31 seems to have a 
much higher gene induction potential as IL-1α for several AMPs (Figure 15). This may be 
an indicator for synergistic effects between the IL-31 and additional downstream signaling 
pathways in inducing AMP expression. Moreover the expression pattern of the different 
AMPs upon IL-31 treatment varies. Observations comparable to those of the structural 
proteins were made, where FLG was identified as a sensitive marker for IL-31 treatment 
(Cornelissen et al., 2012b). The same experimental setup was used to analyze the AMP 
gene expression. In this setting DEFB103A was already induced 20-fold after a 2 h IL-31 
stimulation whereas induction of DEFB4A and the S100A, S100A8, S100A9 and S100A12 
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required a permanent IL-31 presence (Figure 14). Thus this defines DEFB103A like 
FLG as a sensitive marker. 
Keratinocyte expression and secretion of AMPs represent the first line of defense against 
cutaneous pathogens (Harder et al., 2007; Wiesner and Vilcinskas, 2010). To promote their 
antimicrobial properties AMPs are as well as corneocytes embedded in an acidic lipid 
envelope. This lipid envelope together with the AMPs largely inhibits the growth of 
various microbes (Drake et al., 2008; Elias and Choi, 2005). Increased amounts of the 
AMPs psoriasin, RNase-7, hBD-2 and hBD-3 were found in lesional and non-lesional skin 
and fluids obtained in washings from the skin of AD patients compared to healthy controls 
(Harder et al., 2010; Gambichler et al., 2008; Gläser et al., 2009). 
 
This finding seems to be at odds with the observations of increased superinfection with 
bacteria in patients suffering from AD (Arikawa et al., 2002; Guzik et al., 2005). However 
the increased availability of AMPs in these washings may not reflect the total amounts. 
More likely the reduced or the absence of a lipid barrier in these patients prevents the 
attachment of AMPs to the epidermal layer and thus allows more efficient extraction. 
Furthermore the reduction of desmosomal proteins and the reduction of filaggrin and 
keratins 1 and 10 weaken the skin barrier leading to an increased penetration of bacteria 
into the skin. This is further complicated by the fact that persistent, relapsing and difficult 
to treat S. aureus infections are associated with the formation of a slow growing small 
colony variant phenotype (SCV) (Proctor et al., 2006; Vaudaux et al., 2006). Bacteria 
associated with SCV show reduced susceptibility toward AMPs (Gläser et al., 2014). Of 
note is also that different cytokines associated with the complex cytokine milieu of AD 
lesions may have antagonistic effects on the expression of AMPs by keratinocytes. For 
example the Th2 cytokines IL-4, IL-13 and IL-33 have been shown to inhibit the induction 
of AMPs by TNF-α and IFN-γ (Albanesi et al., 2007). Thus the positive consequence of 
IL-31 on the microbial barrier, as reported here, is most certainly modified by other 
factors, with many potentially reverting or antagonizing the IL-31 effect. Well-designed 
experimental setups will be required in the future to investigate the cytokine interplay the 
AD lesions. 
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BI-FUNCTIONAL ROLE OF IL-31 IN HUMAN SKIN BARRIER 
FORMATION 
Concentration-dependent differences in the effects of IL-31 on the barrier formation and on 
the induction of AMPs were observed (Figure 16). Although low levels of IL-31 did not 
significantly induce AMP gene expression (Figure 16 C) a first positive trend on gene 
induction was indicated. Thus low doses of IL-31 might promote the antibacterial barrier 
(Figure 16 C) without compromising the mechanical barrier, indicated by no significant 
influence on the differentiation markers filaggrin and involucrin, as well as no effect on 
desmosomal gene expression (Figure 16 A and B). This might indicate a potentially 
important physiological role of IL-31. This is supported by the fact that the IL-31RA is 
upregulated by S. aureus α-toxin and staphylococcal enterotoxin B in monocytes (Kasraie 
et al., 2009), suggesting a role in innate immunity. Furthermore PBMCs of AD patients 
secrete significantly more IL-31 compared to those of healthy patients upon stimulation 
with α-toxin and staphylococcal enterotoxin B (Niebuhr et al., 2011). This regulation 
seems to be specific as for example IL31 mRNA is not upregulated in response to herpes 
simplex or influenza virus infection (Sonkoly et al., 2006). The expression of IL-31RA in 
keratinocytes is also stimulated by the inflammatory cytokine IFN-γ and by activation of 
the TLR2 receptor (Kasraie et al., 2011). The activation of the IL-31 signaling network by 
different bacteria and the subsequent production and release of different AMPs by 
keratinocytes is of clinical interest. It is known that eccrine sweat, a complex mixture of 
minerals, proteins and proteolytic enzymes, contains IL-31. While sweat is not harmful to 
healthy skin, it can aggravate the lesions of AD patients. Sweat stimulates IL-1β and IL-
1RA expression in keratinocytes, possibly due to the presence of IL-31, and also contains 
IL-1α and IL-1β (Dai et al., 2013). The presence of these cytokines in human sweat is 
consistent with their anti-microbial function as described here. These findings suggest that 
the induction of IL-1α by IL-31 and the subsequent upregulation of AMPs are independent 
of the IL-31-induced barrier disruption that includes repression of many factors associated 
with the mechanical barrier (Figure 5, Figure 6 and Figure 7). The different immune cells 
that reside in the skin or are recruited into the skin by diverse signaling mechanisms are 
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integrated into a complex network of cells that crosstalk at multiple levels. For example 
IL31 gene expression in mast cells is induced upon treatment with hBDs (hBD-1 to hBD-4) 
and LL-37 (Niyonsaba et al., 2010). By revealing the fact that upon IL-31 stimulation 
keratinocytes release increased amounts of hBD-2 and hBD-3 (Figure 13), a potential feed-
forwardloop could be identified. In this feed-forward loop mast cells are a potential source 
of IL-31 and may on one hand further alter the differentiation of keratinocytes and thus 
promote the pathogenesis of diseases such as AD and on the other hand promote the 
antimicrobial barrier. 
 
In summary, this study reveals bilateral effects of IL-31 on the mechanical and the 
antimicrobial skin barrier. The reduction of the mechanical barrier mediated by genetic 
factors or a deregulated cytokine milieu, these two are likely to cooperate, results in the 
increased penetration with allergens and pathogens. It is likely that in individuals 
genetically susceptible to AD, deregulation of the IL-31 and the IL-1 signaling networks 
promote a feedback loop that can aggravate a proinflammatory environment. The results 
also indicate that pharmacological modulation of IL-31 and IL-1α activity in AD and 
possibly other skin diseases might be therapeutically beneficial. 
IL-31 PROMOTES THE EXPRESSION AND RELEASE OF TSLP 
It was of interest that IL-31 promoted the gene expression in monolayer cell cultures as 
well as the release of TSLP in organotypic 3D models (Figure 17). Beside the effects on 
different immune cells TSLP was shown to induce directly itch on a defined subset of 
neurons (Wilson et al., 2013b). Of note a positive correlation was shown between itch 
intensity and either IL31 mRNA or IL-31 serum levels (Ezzat et al., 2011; Kim et al., 
2011). In many animal models the role of IL-31 in promoting itch was addressed and in all 
models an increase in scratching behavior was observed (Dillon et al., 2004; Gonzales et 
al., 2013; Arai et al., 2013; 2014). As mentioned in the introduction, dorsal root ganglia 
that are meant to be responsible for the sensation of itch express the IL-31 receptor and 
their unmyelinated nerve fibers might be directly stimulated by IL-31 (Cornelissen et al., 
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2012a). Interestingly repeated administration of IL-31 promotes IL-31RA expression in 
dorsal root ganglia (Arai et al., 2014), indicating a further role in chronic itch mediated by 
IL-31. However IL-31–induced itch was significantly reduced in transient receptor 
potential cation channel vanilloid subtype 1 (TRPV1)-deficient and transient receptor 
channel potential cation channel ankyrin subtype 1 (TRPA1)–deficient mice but not in c-
kit or proteinase-activated receptor 2 deficient mice (Cevikbas et al., 2013). The TRPA1 
channel is also necessary to promote TSLP mediated itch behavior (Wilson et al., 2013b). 
Furthermore TRPA1 is necessary to promote chronic itch in a AD mouse model (Wilson et 
al., 2013a). Taken together this indicates a possible link between IL-31 and TSLP in itch 
mediation. 
 
However subcutaneous injection of IL-31 does not induce itch immediately but only with a 
delay of more than 30 min (Hawro et al., 2014). Consistently treatment of keratinocytes 
with IL-31 resulted in TSLP secretion after 30 min (Figure 17) and permanent treatment 
over 10 days with IL-31 triggered also TSLP secretion (Figure 17). This strengthens the 
hypothesis of a link between both cytokines and a possible mechanism for the mediation of 
itch. So far the molecular mechanisms of this potential interaction has not been studied. 
Itch may be even mediated directly via the IL-31RA, which is expressed on a subset of 
neurons which (Bando et al., 2006) or as suggested by the findings above indirectly via the 
release of TSLP. Further studies are necessary to clarify the mechanism. However if it was 
mediated via triggering the TSLP expression it is well possible that the IL-31 – IL-1 axis is 
not involved in itch promotion. This can be concluded from the observation that neither IL-
1α nor IL-1β stimulated TSLP expression (Figure 17 D). 
 
Itch and associated scratching behavior is a central mechanism to aggravate AD symptoms. 
Patients suffering from AD scratch their skin and thereby promote the development of 
lesions and the uptake allergens and pathogens. Beside these physiological implications 
itch is one of the most bothersome symptoms, strongly affecting the quality of life (Raap et 
al., 2011). The prevalence of mental health disorders such as depression, anxiety, conduct 
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disorder, and autism was significant higher in children and adults suffering from AD 
than compared to healthy individuals (Yaghmaie et al., 2013; Schmitt et al., 2009; Yang et 
al., 2010; Hashizume and Takigawa, 2006). Moreover dose-dependent relationship was 
observed between the prevalence of a mental health disorder and the severity of the skin 
disease (Yaghmaie et al., 2013). 
 
In summary the correlation between IL-31 and the mediation of itch makes IL-31 a 
potential therapeutical target in AD. 
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4 CONCLUSION AND PERSPECTIVES 
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The findings in this thesis that IL-31 on the one hand weakens the skin barrier and on 
the other hand regulates the expression of AMPs dependent on induction of the IL-1 
signaling network leads to a more comprehensive understanding of the pathomechanism 
underlying the decreased barrier function and aggravated AD disease, affected by elevated 
IL-31 levels. Moreover these findings indicate a novel role of IL-31 in the human host 
defense by promoting the expression of AMPs. It is from outstanding interest that effects 
mediated by IL-31 were dose dependent and only high doses of IL-31 affected the skin 
barrier, whereas low doses of IL-31 strengthened the antimicrobial barrier. Interestingly 
IL-31 stimulated the secretion and release of TSLP in an in vitro organotypic 3D model 
30 min after treatment. This finding is chronological in line with the induced itch by IL-31 
in healthy and AD volunteers (Hawro et al., 2014). All these findings together suggest that 
IL-31 may not directly interact with either the formation of the skin barrier and mediating 
itch but rather indirectly orchestrates secretion of a plenty of cytokines (IL-1, IL-20, IL24, 
TSLP) from keratinocytes. Through these cytokines IL-31 a variety of effects within the 
skin, and contributes to the pathogenesis of AD. Thus in conclusion this thesis supports the 
hypothesis that high IL-31 levels in AD skin are a cause of AD rather than a symptom. 
Findings made should be concerned when IL-31 is targeted, a complete inhibition of IL-31 
seems to be undesirable. Moreover a potential vicious cycle has been identified, in which 
IL-31 secreted from immune cells upon contact with AMPs leads to the promotion of AMP 
release from keratinocytes (Figure 18). 
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Figure 18: Schematic overview of the interaction of mast cells with keratinocytes.  
Signalling resulting in reduced keratinocyte differentiation, e.g. by IL-31 with mast cells being one source, provokes skin 
barrier defects that allow increased penetration by allergens and pathogens. The skin barrier is also disrupted as a 
consequence of itch-induced scratching. In response to IL-31 keratinocytes produce AMPs and TSLP. As a consequence 
different cells in the skin are stimulated, including mast cells. Together this suggests that a feed-forward loop is activated 
that enhances skin barrier defects and associated symptoms (vicious cycle). AMP, antimicrobial peptide; TSLP, thymic 
stromal lymphopoietin. 
By identifying IL-1 signaling as a downstream effector of IL-31 signaling, it might be of 
interest to identify IL-31 effects on keratinocyte behavior with excluding secondary 
signaling effects of IL-1. In line with this it might also be interesting to identify the role of 
IL-1α as a transcription factor in IL-31 signaling. It has been shown that the N-terminal IL-
1α acts as a nuclear oncoprotein and by this can modulate inflammation (Stevenson et al., 
1997; Werman et al., 2004). And moreover the correlation of IL-31, IL-1α and AMPs 
within the skin of healthy individuals and AD patients has to be analyzed carefully as well 
as the role of the elevated intracellular IL-1β levels in the development of AD. To learn 
more about itch mediating properties of IL-31 it will be helpful to have a closer look on 
TSLP secretion and its contribution to IL-31 mediated itch. 
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EXPERIMENTAL PROCEDURES 
Materials and methods are described according to standard protocols used in the Institute 
of Biochemistry and Molecular Biology, RWTH Aachen University, and modified 
regarding individual differences in experimental procedures. 
CONSUMABLES AND REAGENTS 
Consumables 
Consumables were purchased from:  
Amersham Biosciences, Ansell, Becton Dickinson, Biometra, Bio-Rad, Brand, Braun, 
Corning, Costar, Eppendorf, Falcon, Fisher Scientific, Fuji, Greiner, Kimberlex-Clark, 
Merck, Millipore, Nalgene, Nerbe Plus, Nunc, Roth, Sarstedt, Sartorius, 
Schleicher&Schuell, Stratagene, TPP, VWR 
 
Reagents 
Reagents, with a purity of at least analytical grade, were obtained from: 
Abcam, AbD Serotec, Applichem, BD Biosciences, Biozym, Calbiochem, Cellsignaling, 
Clontech, Difco, Eurogentec, Fermentas, Fluka, GE Healthcare, Hoechst, Gibco, 
Invitrogen, InvivoGen, Jackson Immuno Research, Macherey&Nagel, MBL, Merck, MP 
Biomedicals, New England Biolabs, Novagen, Perkin Elmer, Pierce, Promega, Qiagen, 
Rockland, Roche, Roth, Sigma Aldrich, Stratagene, Tulip Biolabs, Zymo Research 
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Solutions 
All solutions were prepared and stored according to standard protocols used in the Institute 
of Biochemistry and Molecular Biology. 
PBS buffer  
140 mM NaCl | 2.6 mM KCl | 2 mM Na2HPO4 | 1.45 mM KH2PO4 
RIPA lysis buffer 
10 mM Tris, pH 7.4 | 150 mM NaCl | 1% NP-40 | 0.1% SDS | 1% Deoxycholate (DOC) | 
0.5% Aprotinin  
Running buffer (Laemmli), pH 8.3 
25 mM Tris | 250 mM glycine pH 8.3 | 0.1% (w/v) SDS 
4x Sample buffer 
320 mM Tris, pH 6.8 | 40% (v/v) glycerol | 20% (w/v) SDS | 0.5% (w/v) bromophenol blue 
| 200 mM β-mercaptoethanol 
Protein standard 
PageRuler prestained protein ladder 10-170 kDa (Fermentas) or Protein marker VI (10-
245) prestained (AppliChem) 
Semi-dry transfer buffer 
25 mM Tris | 192 mM glycine | 20% (v/v) methanol 
PBS-T 
PBS | 0.05% (v/v) Tween® 20  
Blocking buffer 
5% (w/v) skim milk powder (AppliChem) in PBS-T 
Ponceau S solution 
0.2% (w/v) Ponceau S in 3% (v/v) trichloroacetic acid (TCA) 
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Oligonucleotides 
Table 2: qPCR primers 
qPCR primers and Taq Man Probes 
Gene Sequence / catalogue number 
hypoxanthine guanine 
phosphoribosyl transferase 
(HPRT) 
forward: 5’-TGACACTGGCAAAACAATGCA-3’; reverse: 
5’-GGTCCTTTTCACCAGCAAGCT-3’ 
OSMRb forward: 5’-GTGTGGGTGCTTCTCCTGCTTC-3’; reverse: 5’-TCTGTGCTAATGACTGTGCTTG-3’ 
DEFB4A QT01852277 
DEFB103A QT01529535 
S100A7 QT00018746 
S100A8 QT12503907 
S100A9 QT00018739 
S100A12 QT01860873 
FLG QT02448138 
KLK7 QT00028343 
CASP14 QT00046011 
DSC1 QT00047971 
DSC2 QT00016128 
DSG1 QT00001617 
DSG4 QT00064687 
CDSN QT01192625 
JUP QT01003170 
CGN QT00005446 
DSP QT00085218 
CLDN1 QT00225764 
CGNL1 QT00024808 
OCLN QT00081844 
IL1A QT00001127 
IL1B QT00021385 
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IL1R1 QT00081263 
IL1R2 QT00006972 
IL1RN QT00014238 
IL20 QT00044905 
IVL QT00082586 
FLG Hs00418578_m1 
S100A7 Hs00161488_m1 
DEFB4A Hs00823638_m1 
HPRT Hs99999909_m1 
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Antibodies 
Table 3: Antibodies 
Primary antibodies 
Antigen Species Company / cat.no Information 
Filaggrin Mouse Santa Cruz/sc-66192  
IL1a Rabbit Santa Cruz/sc-1253 
 
 
IL1R1 Rabbit Abcam/ab40774  
IL1R2 Mouse Abcam/ab89159  
S100A7 Mouse ABDSerotec/MCA5253Z  
HBD-2 Rabbit Abcam/Ab63982  
STAT3 Rabbit Santa Cruz/sc-8019  
(p-)STAT3 Rabbit Cell signaling/9131S Tyr705 
p38 Rabbit Santa Cruz/sc-7149  
(p-)p38 Mouse Cell signaling/9219 Thr180/Tyr182 
p65 Rabbit Cell signaling/3987  
(p-)p65 Rabbit Cell signaling/3031  
IkBa Rabbit Cell signaling/9242  
Tubulin Mouse Sigma/T-6557  
Actin Rabbit Sigma/A2066  
Secondary antibodies 
Antigen Species Company/cat.no Information 
α-rabbit IgG+IgM goat Jackson Immuno Research HRP-conjugated 
α-mouse IgG+IgM goat Jackson Immuno Research HRP-conjugated 
α-rabbit IgG+IgM goat Invitrogen Alexa Fluor 488-conjugated 
α-mouse IgG+IgM goat Invitrogen Alexa Fluor 488-conjugated 
α-rabbit IgG+IgM goat Invitrogen Alexa Fluor 555-conjugated 
α-mouse IgG+IgM goat Invitrogen Alexa Fluor 555-conjugated 
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INHIBITORS AND CYTOKINES 
Table 4: Inhibitors 
 
Table 5: Recombinant human Cytokines 
CELL LINES 
HaCaT 
HaCaT cells are a spontaneously transformed cell line derived from keratinocytes of 
histological normal skin of a 63 years old male (Boukamp et al., 1988) and were a 
generous gift of N. Fusenig. 
HaCaT-IL31RA 
HaCaT derived cell line containing a stably integrated cassette that leads to the expression 
of a HA-tagged IL-31RA upon doxycycline addition to the cell culture medium. The cell 
line was generated by lentiviral infection of wt HaCaT cells with the vector pSLIK-
IL31RA-HA. 
Inhibitors 
Name Target Company / cat.no Final concentration 
UO126 MEK1 Calbiochem/662005 20 µM 
SB202190 p38 Calbiochem/559388 20 µM 
Jak Inh I JAK kinase Calbiochem/420099 100 nM 
JNK Inh I JNK kinase Calbiochem/420119 20 µM 
Wortmannin PI3-kinase Calbiochem/69675 500 nM 
Anakinra IL1 receptor Swedish Orphan Biovitrum 3 µg/ml 
Recombinant human Cytokines 
Antigen  Company / cat.no Final concentration 
rhIL-31  Peprotech/200-31 100 ng/ml 
rhIL-1 alpha  Peprotech/200-01A 10 ng/ml 
rhIL-1 beta  Peprotech/200-01B 50 ng/ml 
rhIL-20  R&D/1102IL 20 ng/ml 
rhIL-24  R&D/1965IL 20 ng/ml 
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METHODS 
METHODS IN MOLECULAR BIOLOGY 
RNA isolation and cDNA synthesis 
RNA was isolated from cells using Qiagen QIAshredder colums and RNeasy Kit with the 
optional on-column DNase digestion (RNase-free DNase Set, Qiagen) according to 
manufacturer’s protocol. In case of organotypic 3D models, tissues were primarily 
mechanically disrupted and homogenized by using a tissue lyzer (Qiagen). RNA was 
eluted from the column in 20 µl TE buffer. RNA purity and concentration were determined 
with the NanoDropTM device. 1 µg of RNA was reverse transcribed into complementary 
(c)DNA using QuantiTect Reverse Transcription KitTM (Qiagen) following company’s 
manual. cDNA was diluted 1:10 with TE and analyzed by quantitative Real-Time PCR or 
stored at -20 °C. 
qPCR 
To determine the gene expression quantitative PCR (qPCR) was used. The process of 
qPCR is based on the principle of conventional PCR with the fluorescent dye SYBR Green 
providing the quantification of amplified DNA. The dye incorporates into double-stranded 
DNA and emits a light signal after excitation at a specific wavelength. The emitted 
fluorescence signal is detected after each elongation step within a PCR cycle in Real Time. 
Thereby the fluorescence increases proportionally to the amount of PCR product and thus 
allows calculated conclusions on the amount of PCR product. 
Experiments were either run on a Rotor-Gene 6000/Q (Corbett/Qiagen) in 10 µl reaction 
volume using SensiFast™ SYBR No-ROX Kit (Bioline). TaqMan® experiments were 
carried out in 25 µl on an ABI PRISM 7300 sequence detection system (Applied 
Biosystems) using Assay-on-Demand gene expression products (Applied Biosystems).  
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Table 6: PCR pipetting scheme 
PCR pipetting scheme 
2x SensiFast™ 5 µl 
QuantiTect primer assays 1:4 diluted in TE 
individually ordered oligonucleotides, 100nM, 
1:40 diluted 
1 µl 
DNA template cDNA (1:20) 2 µl 
RNase-free H2O ad 10 µl 
 
Table 7: PCR program 
PCR program 
Step Temperature Time Cycles 
initial denaturation 95 °C 10 min  1 
denaturation 95 °C 15 sec 
40 cycles 
annealing 60 °C 15 sec 
elongation 72 °C 15 sec 
Melting curve 60-95 °C in 0.5 °C steps 5 sec each step  
 
Table 8: TaqMan® pipetting scheme 
PCR pipetting scheme 
TaqMan® Gene Expression Master Mix 12.5 µl 
Taqman probe 1.25 µl 
DNA template cDNA 5 µl 
RNase-free H2O ad 25 µl 
 
Table 9: TaqMan® program 
PCR program 
Step Temperature Time Cycles 
initiation 50°C 2 min  1 
initial denaturation 95 °C 10 min 1 
denaturation 95 °C 15 sec 
40 cycles annealing and 
elongation 
60 °C 60 sec 
 
Relative mRNA expression was calculated by the comparative Ct method and normalized 
to the housekeeping gene HPRT (hypoxanthine guanine phosphoribosyl transferase) using 
Rotor-Gene Q software. In the text the whole procedure from isolating RNA over cDNA 
synthesis and qPCR processes were combined and named as qRT-PCR. 
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METHODS IN CELL BIOLOGY 
Human cell cultivation 
All cell lines were incubated in humidified atmosphere at 37 °C with 5% CO2. HaCaT, 
HaCaT-IL31RA and Human dermal fibroblasts cells were cultivated under adherent 
conditions in DMEM-GlutaMAX I (Gibco), supplemented with 10% heat-inactivated fetal 
calf serum (FCS, Gibco). NHEK (Normal human epidermal keratinocytes) were cultivated 
in KGM supplemented with BPM, hEGF, insulin and hydrocortisone. To sustain stability 
of the integrated vector the medium of HaCaT-IL31RA were supplemented with 
800 µg/ml geniticin (G418). 
 
Seeding and passaging of cells 
For passaging the cells medium was exhausted and the cells were once carefully washed 
with PBS. All cell lines were incubated in Trypsin / EDTA (0,5%/0,02%, NHEKs: 
0,25%/0,01%) until they detached from the plastic surface, medium was added to stop the 
process of trypsinization. Subsequent cells were counted either using the Casy Cell 
Counter system (Innovatis) or a chamber slide and the cells were seeded in the appropriate 
dilutions in new culture plates.  
 
Cryoconservation 
For cryoconservation, 80% confluent adherent cells were removed from dishes by 
trypsinization. Cells were pelleted by centrifugation. The cell pellet was re-suspended in 
1 ml FCS containing 10% DMSO (v/v) and transferred into a cryotube. Tubes were frozen 
down to -80°C using a Mr. FrostyTM (Sigma Aldrich) freezing container. For long-term 
storage, tubes were transferred to -150 °C.  
For cell thawing, tubes were quickly warmed in a 37 °C water bath and directly transferred 
into 9 ml prewarmed cell culture medium. Cells were centrifuged and again re-suspended 
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in 10 ml prewarmed cell culture medium. Finally cells were seeded in the appropriate 
dilutions in new culture plates. 
Isolation of HDFs and NHEKs 
Normal human epithelial keratinocytes (NHEKs) and human dermal fibroblasts (HDFs) 
were prepared from sterile human skin samples (approved by the ethic committee of the 
Medical School of the RWTH Aachen University). Yvonne Marquard (Dermatology 
Department, Medical School, RWTH Aachen University) isolated HDFs and NHEKs from 
human skin samples. 
 
Normal human keratinocytes were isolated from skin biopsies of adult skin and foreskin. 
The biopsies were rinsed with 70% ethanol, washed 3 times in PBS with antibiotics / 
antimycotics and cut into pieces of 1cm2. To separate dermis and epidermis these pieces 
were incubated in 50 units/ml Caseinolytic Dispase (BD Bioscience) for a minimum of 2h 
at 37°C. Single cell suspension of keratinocytes was released by gentle pipetting after 
incubation for 30 min at 37°C in 0.25 mg/ml trypsin/EDTA (Lonza). The Trypsin 
Neutralisation Solution TNS (Lonza) inactivated the remained trypsin. Human dermal 
fibroblasts (HDF) were isolated by incubating the remaining dermis in dispase. Afterwards 
collagenase 1A 100U/ml (Sigma) digestion was performed. The generated single cell 
suspensions was seeded in the appropriate dilutions as described before.  
Keratinocytes were used in their first to second passage for organotypic skin equivalents or 
monolayer cultures. 
NHEK and HaCaT skin equivalents 
NHEK skin equivalents were constructed as described in (Neis et al., 2010). To construct 
either HaCaT or HaCaT-IL31RA skin equivalents bovine collagen type I was mixed in a 
ratio 8:1 with HBSS (Gibco) w/o Ca2+/Mg- and 1 M NaOH was added to neutralize the pH. 
1 ml collagen gel was added on top of a 6-well insert with 3.0 µm pore size and incubated 
for 1 h at 37°C. HDFs with a cell number of 4x106 cells/ml were suspended in FCS. In a 
ratio of 8:1:1 bovine collagen, HBSS and HDFs were mixed. The pH of the collagen, 
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HBSS solution was neutralized with 1 M NaOH before adding the cells. 3 ml of this 
suspension were plated onto each gel made before. The new formed gels were incubated 
for 3 h at 37°C. For the next day HaCaT 3D medium, normal HaCaT culture medium as 
described before supplemented with 50 µg/ml ascorbic acid was added below and above 
the gel. At the next day 4x106 HaCaT cells in 2 ml medium were added on top of the 
model. After 2-3 h of incubation at 37°C and 5% CO2 2 ml additional medium was given 
to the cells. At least the model was lifted to the air liquid interphase after 2 days of co-
cultivating HDFs and HaCaT. 
 
Cell-sorted skin equivalents (CsSE) 
CsSE were based on protocols as described previously (Wang et al., 2000; Neis et al., 
2010). Briefly, 48 h before implantation, 4-6 weeks old SCID / NOD mice were fed with 
doxycycline (2 mg/ml) provided in the drinking water supplemented with 5% sucrose. On 
day -1 two silicon chambers were implanted onto the muscle fascia of the mouse back. 
24 h later a cell slurry of 1-2 million HDFs and HaCaT cells (chamber 1) or HDFs and 
HaCaT-IL31RA cells (chamber 2) were seeded into the chambers. From day 4 to 7, 
20 µg/ml rhIL-31 (or PBS as control) were applied subcutaneously under the skin 
equivalents. On day 6 the chambers were removed followed by TEWL measurements on 
day 7. Mice were sacrificed and skin equivalents were either embedded in paraffin or 
cryoconserved for further investigation. Philipp M. Amann, Yvonne Marquard and Jens M. 
Baron (Dermatology Department, Medical School, RWTH Aachen University) planned 
and conducted the animal experiments. 
 
Skin barrier analysis 
For skin barrier analysis fluorescently labeled recombinant timothy grass pollen major 
allergen, phl p1 (Biomay, Vienna/Austria) was applied topically on a 7 day-old HaCaT-
IL31RA organotypic skin equivalents for 45 min and analyzed by immunofluorescence. To 
analyze the vulnerability of an organotypic skin equivalent to the penetration by irritating 
agents, 7 day-old HaCaT-IL31RA organotypic skin equivalents were treated topically with 
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0.2% SDS for 40 min and 24 h later the expression of IL1A was analyzed by qRT-PCR 
and the IL-1α release was measured by ELISA. 
 
Penetration assay 
HaCaT-IL31RA models were treated with 10 mM Lucifer Yellow / Biocytin (Invitrogen, 
L6950) at room temperature for 1 h. Models were subsequently processed for 
cryoconservation.  
 
Transepidermal water loss analysis in cell-sorted skin equivalents 
TEWL was measured using a Tewameter TM210 (Courage+Khazaka, Cologne, Germany) 
according to the protocol of the manufacturer. 
 
METHODS IN PROTEIN BIOCHEMISTRY  
Protein sample preparation 
From cells 
To prepare whole cell protein lysates, adherent cells were washed with ice-cold PBS. 
Subsequently, 300 µl RIPA lysis buffer plus freshly added Protease Inhibitor cocktail was 
added per 10 cm dish. Adherent cells were collected by scraping and transferred to an 
Eppendorf tube. RIPA lysates were sonicated in a water-bath sonicator (Bioruptor®, 
Diagenode) for 15 min with 30-second cycles at maximum intensity and were subsequently 
centrifuged at 13,000 x g, for 30 min at 4 °C. Supernatants were transferred to a new 
Eppendorf tube and stored at -80 °C or directly analyzed by SDS-PAGE or ELISA. 
Lowry Assay 
Lowry assay was performed using the RC/DC Protein Assay Kit from Bio-Rad according 
to the manufacturers protocol. In brief 20 µl of reagent S was mixed with 1 ml of reagent A 
to obtain A’.Subsequently 25 µl reagent A’ were mixed with 200 µl B and added to the 
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RIPA cell-lysate in a 96 well plate. The lysate and reagent were incubated for 15 min at 
RT and wavelength at 750 nm was read. For determination of the protein amounts in the 
unknown samples a BSA standard curve was used. 
SDS-PAGE  
Proteins were electrophoretically separated under denaturing conditions in discontinuous 
sodium dodecyl sulfate polyacrylamide gels (SDS-PAGE) according to the method 
described by Laemmli (Laemmli, 1970). SDS running gels were prepared with 10-15% 
acrylamide, depending on the size of the analyzed protein. Independent from the running 
gel, stacking gels contained 5% acrylamide. Prior to loading, protein samples were mixed 
with 4x sample buffer and boiled for approx. 3 min. Separation of gels was performed in a 
BioRad electrophoresis cell filled with Laemmli running buffer. In order to estimate 
protein sizes, a protein standard was also applied to each SDS-PAGE. 
Western blot and immunodetection 
Separated proteins were transferred from acrylamide gel onto a nitrocellulose membrane 
(Millipore) using the semi-dry Western blotting system. Gel, nitrocellulose membrane and 
Whatman filter paper soaked with semi-dry transfer buffer were placed between the two 
electrode plates of a blotting chamber. Transfer was performed for 70 min with 
1.5 mA/cm2
 
of nitrocellulose membrane. To confirm successful protein transfer, membrane 
was stained with Ponceau S solution for 2 min.  
For immunological detection, the membrane was blocked with 5% non fat dry milk in 
PBS-T for a minimum of 30 min and subsequently incubated at 4 °C overnight with 
primary antibody in PBS-T. After removing residual antibodie wiht three washing steps in 
PBS-T, membrane was incubated for 1 h at RT with HRP-coupled secondary antibody in 
PBS-T. The detection was performed by using horseradish peroxidase–labeled secondary 
antibodies with either ‘‘Chemiluminescence ECL kit’’ (Pierce/Thermo Scientific, 
Rockford, Ill) or ‘‘SuperSignal West Femto Maximum Sensitivity Substrate’’ (Pierce). 
This substrates for HRP resulted in chemiluminescence signals, and were immediately 
detected by LAS-3000 Imager (Fujifilm). 
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Flow cytometry 
Cells were detached from the surface as described before. 1x106 cells per sample were 
washed twice with PBS, and 1 ml 3.7% PFA was added under vortexing conditions. Cells 
were incubated for 20 min at RT, wash twice with PBS/1%BSA and blocked for 30 min in 
the same solution. After blocking the cells, 200 µl primary antibody was added for 1 h at 
RT. Samples were washed twice with PBS/1%BSA and incubated with 200 µl secondary 
antibody for 20 min at RT in the dark. Finally the cells were washed three times with 
PBS/1%BSA and resuspend in 500 µl PBS/1%BSA. The cell surface fluorescence 
intensity was measured on a FACS- Canto flow cytometry system (BD, Franklin Lakes, 
NJ, USA). 
 
ELISA 
Cells were treated as described in the figure legends and lysed in RIPA buffer as described 
before (Pandithage et al., 2008) or the supernatants were collected. The samples were 
either directly applied to the ELISA or diluted in the provided dilution buffer, and 
measured according to the manufacture’s recommendations. 
 
Table 10: ELISA  
ELISAs 
Gene Company / cat.no 
IL1A R&D/DY200 
IL1B R&D/DY201 
S100A7 Cloud-Clone Corp/SEC035HU 
S100A9 Cloud-Clone Corp/SEB793HU 
S100A12 Cloud-Clone Corp/SEB080HU 
HBD-2 Peprotech/900-K172 
HBD-3 Cloud-Clone Corp/SEE132Hu 
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HE staining of organotypic skin models 
4 µm thin slices were cut from cryo-conserved three dimensional skin equivalents or CsSE 
and transferred onto microscope slides. 5 min staining with hemalum followed by 10 min 
incubation in water that increases the pH of the samples, colors acidic structures like 
nucleus and ER (and a few other objects) blue. A basic counterstaining with an aqueous 
solution of 0.1% eosin, which colors other, basic structures in various shades of red, 
follows the nuclear staining. Eosin is removed by washing two times for 3 min in water. 
The water within the samples is removed by 70% ethanol followed by washing two times 
for 3 min in 90% ethanol and two times for 3 min in 100% ethanol. Finally the slides were 
washed two times for 3 min in Xylol and embedded with Vitro Clud® (Langenbrinck) 
under a cover slip.  
Immunostaining of organotypic skin models 
For light microscopy and immunofluorescence analyses of the 3D skin models, 4 µm slices 
were cut from cryo-conserved three dimensional skin equivalents and transferred onto 
microscope slides. The slices were air dried and washed once with PBS w/o Ca2+/Mg+. 
Primary Antibody was diluted in Antibody dilutent (Dako) and incubated for 1 h at RT. 
The slides were washed three times with PBS and then secondary fluorescently labeled 
antibody was diluted in Antibody dilutent (Dako) and incubated for 1 h at RT in the dark. 
The slices were washed again with PBS and nuclear staining was performed for 5 min with 
DAPI 1:5000 in ddH2O. Finally the slices were washed three times with ddH2O and 
mounted under a cover slip with mouning medium (Dako). 
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 ABBREVIATIONS 
Abbreviations 
Abbreviated form full text form 
°C degree Celsius 
3D  three dimensional 
A  ampere 
A. dest  destilled water 
aa  amino acid 
AAM alternatively activated macrophage 
Ab  antibody 
ACD  allergic contact dermatitis 
AD  atopic dermatitis 
AE  atopic eczema 
AKT  v-akt murine thymoma viral oncogene homolog 1 
Amp ampicillin 
ATCC American Type Culture Collection 
bio biotin 
Bp base pair 
BSA  bovine serum albumin 
ca.  circa 
CBD  cytokine binding domain 
CCL  CC chemokine receptor ligand 
CD  cluster of differentiation 
CD  Crohn’s disease 
Cdc2  CDK1, cyclin-dependent kinase 1 
CDK cyclin dependent kinase 
cDNA copy DNA 
CE  cornified envelope 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HGF hepatocyte growth factor 
HPRT hypoxanthine guanine phosphoribosyl transferase 
hr(s) hour(s) 
HRP horse radish peroxidase 
hyg hygromycine 
i.e. that is 
IF immunofluorescence 
IFN interferon 
Ig  immune globulin 
IGF insulin like growth factor 
IL Interleukin 
IL-31RA IL-31 receptor alpha 
INV  Involucrin 
IRF interferon regulatory factor 
ITGB4  β 4-integrin 
JAK janus tyrosine kinase 
JNK Jun N-terminal kinase 
K keratin 
k  kilo 
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KGF keratinocyte growth factor 
Ki67  antigen identified by monoclonal antibody Ki 67 
KO knock out 
l  liter 
LCE late cornified envelope 
LDH lactate dehydrogenáse 
LPS  lipopolysaccharide 
m  milli 
M molar (Mol/l) 
MAPK  mitogen activated protein kinase 
MAPKAPK2 mitogenic activated protein kinase activated kinase 2 
max  maximum 
MB  mega bases 
MC  mast cell 
MEK  MAP2K, mitogen-activated protein kinase kinase 
min minimum 
min minutes 
MMP matrix metallo- proteases 
mRNA  messenger RNA 
n  nano 
NCID notch intracellular domain 
Neo neomycin 
NFκ -B nuclear factor kappa B 
NHEK normal human epidermal keratinocyte 
NP-40 Nonidet P-40 
OSM  oncostatin M 
OSMR oncostatin M receptor 
OVA  ovalbumin 
PAGE  polyacrylamide gel electrophoresis 
PBMC peripheral blood mononuclear cell 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PEG  poly-ethylene glycol 
PI3-K  Phosphoinositide-3-kinase 
PKB/C protein kinase B/C 
PKC  protein kinase C 
rh  recombinant human 
RNA ribonucleic acid 
ROS  reactive oxygen species 
rpm  rounds per minute 
qRT-PCR  quantitative reverse transcriptase polymerase chain 
reaction SB  stratum basale 
SC  stratum corneum 
SDS  sodium dodecyl sulfate 
SEB  superantigen staphylococcal enterotoxin B 
SEMF  Human colonic subepithelial myofibroblast 
SG  stratum granulosum 
shRNA  small hairpin RNA 
SNP single nucleotide polymorphisms 
SOCS suppressor of cytokine signaling 
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SPF  specific pathogen free 
SPR  small proline rich 
SS  stratum spinosum 
STAT  signal transducers and activators of transcription 
TE  Tris-EDTA 
TG  transglutaminase 
TGF  transforming growth factor 
TIMP-1  TIMP metallopeptidase inhibitor 1 
TLR toll like receptor 
TNF  tumor necrosis factor 
TRE tetracycline responsive element 
TSB  tryptic soy broth 
Tyr, Y tyrosine 
U unit 
UV  ultra violet light 
v/v  volume per volume 
VEGF vascular epithelial growth factor 
w/v weight per volume 
WB  western blot 
WT wild type 
x  times/-fold 
β -ME  β -mercaptoethanol 
λ  wavelength of light 
μ  micro 
OMIM® Online Mendelian Inheritance in Man® 
ICD-10 International Classification of Diseases 
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